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Abstract: Macro-autophagy (autophagy) is a highly conserved eukaryotic intracellular process of 
self-digestion caused by lysosomes on demand, which is upregulated as a survival strategy upon 
exposure to various stressors, such as metabolic insults, cytotoxic drugs, and alcohol abuse. Para-
doxically, autophagy dysfunction also contributes to cancer and aging. It is well known that regu-
lating autophagy by targeting specific regulatory molecules in its machinery can modulate multiple 
disease processes. Therefore, autophagy represents a significant pharmacological target for drug 
development and therapeutic interventions in various diseases, including cancers. According to the 
framework of autophagy, the suppression or induction of autophagy can exert therapeutic proper-
ties through the promotion of cell death or cell survival, which are the two main events targeted by 
cancer therapies. Remarkably, natural products have attracted attention in the anticancer drug dis-
covery field, because they are biologically friendly and have potential therapeutic effects. In this 
review, we summarize the up-to-date knowledge regarding natural products that can modulate 
autophagy in various cancers. These findings will provide a new position to exploit more natural 
compounds as potential novel anticancer drugs and will lead to a better understanding of molecular 
pathways by targeting the various autophagy stages of upcoming cancer therapeutics. 
Keywords: autophagy; natural products; anticancer drugs; mTOR signaling; autophagy  
modulators; resveratrol; ω-3 PUFAs 
 
1. Introduction 
Cellular homoeostasis requires a stable balance between biosynthetic renewal and 
catabolic processes. Macro-autophagy, hereafter referred to as autophagy, and the ubiq-
uitin-proteasome system (UPS) are two primarily distinct proteolytic systems in eukary-
otic cells that have wide-scale degradation [1]. Given that highly selective UPS can gener-
ally only recognize short-lived protein substrates in the cell renovation system, autophagy 
has been well-appreciated and has followed a complex model of execution [2]. Autophagy 
is a self-digestive process that facilitates eukaryotic intracellular nutrient recycling via the 
lysosomal degradation of long-living, unwanted cellular proteins as well as damaged or 
defective organelles, including the mitochondria, the endoplasmic reticulum (ER), the 
Golgi apparatus and peroxisomes [3,4]. Autophagy has an established role in cell metab-
olism and energy homeostasis through the catabolism of proteins, lipids (lipophagy), car-
bohydrates (glycophagy) and iron (ferritinophagy), which fuels energy and nutrient 
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stores [5]. In response to a wide variety of cellular stressors, including metabolic stress, 
autophagy is typically activated as a pro-survival mechanism in normal and cancerous 
cells [6,7]. However, in recent years, accumulated evidence has concentrated on the im-
portance of autophagy and the variety of roles it plays in a variety of human diseases, 
including cancers. For instance, alterations in autophagy and inherited mutations in au-
tophagy-related genes (ATGs) that regulate autophagy have been implicated in human 
cancer [4,8,9]. Autophagy has complex and context-dependent actions in cancers, and in-
terventions to activate and suppress it have been planned as cancer therapies [4,10]. Thus, 
this review on natural products may reveal new therapeutic strategies that can regulate 
the progression of autophagy-mediated disorders, particularly cancers. 
Today, although many chemotherapeutic agents have been developed to treat can-
cer, the effectiveness of many cancer medications remains limited or unsatisfactory. 
Therefore, the development of effective and non-toxic anticancer drugs or strategies is 
highly urgent and desirable. In the last few decades, a series of natural products with the 
ability to regulate physiological functions have been isolated and exploited from plants, 
animals and microorganisms, with most of them revealing obvious anticancer activity 
[11–14]. Well-tolerated and less toxic natural products will help patients to achieve better 
therapeutic results and will improve quality of life. Many chemotherapeutic agents have 
been identified by investigating potential compounds from plants, animals, and microor-
ganisms, including marine organisms, which have been found to exert anti-cancer effects 
against a variety of tumors [11–14]. As a result, over 49% of approved and pre-DPA ap-
plications are natural products or agents derived from natural products, with the excep-
tion of antibodies and vaccines [15]. With respect to antitumor agents, more than 53% of 
anti-cancer agents applied in medicine are unaltered natural products, botanical drugs 
(defined mixture) and derivatives of natural products [16]. To develop an effective au-
tophagy-targeting therapy, it is essential to identify key targets in the autophagy pathway 
in order to develop novel therapeutics. As discussed earlier, autophagy can play a protec-
tive or destructive role in the state of a disease, and thus it would be valuable to identify 
and develop pharmacologic agents that can exactly induce or inhibit this cellular process. 
A wide variety of potentially “druggable” targets in different stages of autophagy have 
been identified [4,9,17], and several natural products are capable of inducing and/or in-
hibiting autophagy, as discussed in this paper. 
2. Molecular Mechanisms and Morphological Features of Autophagy 
The following specific stages of autophagy are involved in the execution of the final 
degradation stage of recycling and energy production (Figure 1). The ultrastructural fea-
tures of autophagy are shown in Figure 2.  
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Figure 1. Molecular mechanisms of various stages of autophagy. Autophagy is activated in response to various cellular 
stresses and is triggered by a decrease in rapamycin complex 1 (mTORC1) activity due to the activation of AMP-activated 
protein kinase (AMPK) or p53 signaling. mTORC1 suppresses the activity of Unc-51-like autophagy activating kinase 1 
(ULK1) complex. Therefore, inhibition of mTORC1 causes the initialization of the ULK1-mediated formation of the isola-
tion (autophagosomal) membrane (IM) in association with the class III phosphatidylinositide 3-kinase (PI3K) complex 
(PI3KC3). The IM expands into an autophagosome (AP) with a double-layer membrane, which can engulf any cellular 
component, including proteins, damaged organelles and lipid droplets. The AP merges with the lysosome (via LAMP-1, 
2), forming autophagolysosome (APL) or autolysosome (AL), and resulting in the degradation of the cargo by cathepsins 
and the autophagic lysosome reformation (ALR). The nucleation, elongation and maturation of the IM are dependent on 
two ubiquitin-like conjugation systems (ATG12 and ATG8), which involve multiple autophagy proteins, including Be-
clin1, ATG5, ATG16 and MT-associated protein 1 light chain 3 (LC3). The AL provides an acidic milieu for hydrolytic 
enzymes to digest the engulfed components. Nuclear localization of transcription factor EB (TFEB) is critical to the for-
mation of lysosomes and to the enhanced expression of autophagy proteins. Importantly, autophagy could be selective of 
mitochondria (mitophagy) or ER (ER-phagy) [7]. However, the detailed mechanisms of this selected autophagy are beyond 
the scope of this study. 
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Figure 2. Ultrastructural features of upregulated autophagy in ethanol-treated Sertoli cells (ETR 
SCs). TEM of the control (A) and ETRs (B–G). The histogram (H) shows a significant increase in the 
number of autophagic vacuoles (AVs) in ETR SCs. The long black arrows indicate autophagosomes 
with a double limiting membrane (arrow heads) (magnified in the inset in (C)). The short arrows 
indicate autolysosomes. The broken arrows in (E) show multilamellar bodies, while the white ar-
rows in (G) show autophagosomes containing fragmented mitochondria. Note the characteristic 
perinuclear localization of AVs. S: SC nucleus; L: lysosome; M: mitochondria; LD: lipid droplet. AVs 
include autophagosomes and autolysosomes. * p < 0.05. This was reprinted from Reference [3]. 
2.1. Autophagy Initiation 
Autophagy is initiated by a network of complex molecular machineries that centrally 
involve a set of ATG proteins that modulate IM (originally termed as the phagophore) 
formation and autophagosome maturation. Under cellular stress, the serine/threonine 
protein kinase ULK1 and class III PI3K complexes are the two major protein structures 
involved in the initiation of autophagy in mammalian cells. It has been reported that 
mTORC1 inhibits the ULK1 complex, while AMPK acts as a positive regulator of ULK1 
by suppressing mTORC1 in nutrient-sensing pathways (Figure 1) [18,19]. The origin of 
the membrane for the formation of autophagosome has been studied thoroughly, but re-
mains an enigma in the field of autophagy [20]. While electron microscopic static images 
provide detailed morphological data, they do not completely explain the dynamics of au-
tophagy, especially the sequential completion of autophagosomes and the fusion with ly-
sosomes. Live-cell imaging techniques suggest that effective vesicular trafficking from ex-
isting compartments and membranes involves IM formation [10,21,22]. Several organelles, 
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such as the ER [20], the Golgi apparatus, the mitochondrial outer membrane (MOM), en-
dosomes, the plasma membrane and the nuclear envelope [23], may donate membranes 
for IM formation. It was also found that the specialized ER regions called ER exit sites 
(ERES) are important mediators for IM formation [20]. Moreover, several inter-organelle-
contact sites have emerged as dynamic spots for the lipid transition between the mem-
branes and the growth of nascent IM. ER–mitochondria contact sites, also known as mito-
chondria-associated ER membranes (MAMs), are claimed to be the source of IM [24,25]. 
MAMs spatially overlap with specialized membrane compartments, called omegasomes 
(omega-shaped structures), and these serve as a cradle of IM formation and autophago-
somal vesicles close to the ER. 
2.2. Cargo Nucleation, Elongation and Enclosure of IM 
During the initiation of autophagy, the localization of the ULK1 complex in the IM 
site regulates the vesicle nucleation machinery. The nucleation machinery of the initial IM 
is dependent on local phosphatidylinositol 3-phosphate (PI3P) production, which is 
marked by its binding protein, i.e., the double FYVE domain-containing protein 1 (DFCP1) 
by the class III PI3K complex. Thus, vesicle nucleation involves the ULK1 complex mech-
anistic link core complex, which consists of class III PI3K (PIK3C3), Beclin1, p150, ATG14L 
and the activating molecule in Beclin1-regulated autophagy protein 1 (Ambra1) [26,27]. 
The elongation step of the IM is controlled by two evolutionarily conserved ubiquitin-like 
(UBL) conjugation systems called the ATG12–ATG5–ATG16 complex (also known as the 
ATG12 conjugation system) and the LC3-phosphatidylethanolamine (LC3-PE) conjuga-
tion system [28,29] (Figure 2). 
In response to various stressors, such as starvation, oxidative stress and hypoxia, spe-
cific cargos are sequestrated with autophagy receptors in IM. The autophagy receptors 
bind specifically to ubiquitinated cargos that are tagged with degradation signals of the 
autophagy machinery through their LC3 interacting regions (LIR) [30,31]. In general, the 
LIR motifs interact with autophagy regulatory proteins of the LC3/GABARAP family [32]. 
In mammalian cells, more than twenty autophagy receptors have been identified, and se-
questosome-1 (p62) is one of the most common autophagy receptors [33]. LC3-II is the 
major autophagy marker, and its upregulation is an indicator of autophagy activation and 
the formation of dual-membrane autophagosomes. Using immunofluorescence and im-
munohistochemistry (IHC) methods, the autophagosomes appear as dots or puncta, indi-
cating the expression of LC3-II, which could be detected as shown in Figure 3 [3,7]. An 
autophagic flux involves the formation of autophagosomes, their administration to lyso-
somes, and the subsequent degradation and release of degraded macromolecules into cy-
tosol, which are then recycled. This is called productive or completed autophagy. Thus, 
the increases in the level of LC3-II, as evidenced by the accumulation of autophagosomes, 
are not measurements of the autophagic flux per se, but may reflect the induction of au-
tophagy sequestration and/or the inhibition of autophagosome clearance, which results 
from the fusion failure with lysosomes or lysosomal dysfunction. This incomplete or im-
paired autophagic flux may result in cell death, such as apoptosis or cell death with au-
tophagic features (sometimes called autophagic cell death). Autophagic flux can be mon-
itored through the use of inhibitors such as choloroquine (CQ), bafilomycin A1 (Baf A1) 
or lysosomal protease inhibitors. This can be determined by measuring the levels of LC3-
II in both the presence and absence of saturating levels of inhibitors; if flux is occurring, 
the amount of LC3-II will be higher in the presence of the inhibitor [3,7–10]. 
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Figure 3. Expression of LC3 in stromal cells of serious human ovarian carcinoma using IHC. The 
black arrows indicate LC3-II puncta in stromal cells, whereas the red arrows mark ovarian cancer 
cells. The framed area is magnified in the inset. BV, blood vessel. The avidin biotin complex (ABC) 
IHC method is performed. The diaminobenzidine (DAB) is used as a chromogen (brown reaction), 
whereas the hematoxylin (blue) is applied for nuclear counterstaining. 
2.3. Transport of Autophagosomes 
Autophagosomes (double membrane vesicles) are randomly formed throughout the 
cytosol, concentrating and continuously moving during the maturation process. In gen-
eral, microtubules (MTs) serve as an interconnected network of intracellular movement 
powered by specific motor proteins, including the kinesin and dynein protein families 
[34]. Kinesins normally transport the cargoes to the peripheral plus-ends of MTs, whereas 
dyneins, a class of AAA+-ATPase-associated motors, are involved in the delivery of au-
tophagosomes towards the minus-end [35]. The coordinated transport of lysosomes and 
autophagosomes in the perinuclear zone is necessary for the adequate fusion of these two 
organelles [36,37], as shown in Figure 2. Under various stress conditions, the intracellular 
pH increases, resulting in the relocation of lysosomes to the perinuclear region, where 
mature autophagosomes are transported to the same region by the MTs [3,36]. Conse-
quently, the lysosomes in the perinuclear areas merge with mature autophagosomes in 
order to acidify them [3,38]. This is shown in Figure 2. 
2.4. Autolysosome Formation, Vesicle Degradation and ALR Cycle 
As the mature autophagosome docks to the lysosome, a single-membrane autolyso-
some is formed [39]. Merging autophagosomes with late endosomes to form amphisomes, 
prior to fusion with the lysosome, is also reported to increase cargo delivery and reduce 
the pH of autolysosomes [40]. Upon fusion with mature lysosomes, the intralysosomal 
contents degrade with the release of end products into the cytosol, producing local nutri-
ent availability as a source of cellular energy. This process results in the reactivation of 
mTOR, a key regulator of autophagy, and the regeneration of mature lysosomes from au-
tolysosomes, which is a process called ALR [41,42]. While there is significant insight into 
each of these stages of autophagy, the molecular mechanisms controlling the biogenesis 
of autophagosomes, autolysosomes and lysosomes are complex. In response to intracel-
lular and environmental stressors, autophagy is primarily regulated by two critical sig-
naling pathways, i.e., the mTOR-dependent and mTOR-independent signaling pathways, 
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which include Ca2+, inositol 1,4,5-trisphosphate (IP3) receptor (IP3R), AMPK, stress acti-
vated enzyme c-Jun N-terminal kinase (JNK), and B-cell lymphoma 2 (Bcl-2) homology 
(BH) domain 3 (BH3)-only proteins [42]. It has been reported that nuclear translocation of 
TFEB positively regulates the formation of lysosomes and enhances the expression of au-
tophagy proteins, specifically, under starvation, oxidative and nitrative stress (Figure 4). 
Using various methods, we recently provided evidence of the enhanced nuclear translo-
cation of TFEB in the SCs of ETRs, which is correlated with the upregulation of autophagy 
and mitophagy proteins [43], as shown in Figure 4. 
 
Figure 4. Elevated expression and nuclear translocation of TFEB in ETR SCs. (A) The IF of TFEB 
expressions in the control (a) and ETRs (b). The insets present higher magnifications of the framed 
areas. Note the overexpression of TFEB (white arrows) in the SC nuclei of ETRs. (B) Immunogold 
labeling of TFEB (black arrows, 15 nm gold particles) in the control (c) and ETR SCs (d). (C) Western 
blot of TFEB in the control and ETR tests (n = 3). (D) Histogram showing a significant increase in 
TFEB expression in the ETR tests. * p < 0.05 (t-test). (E) IHC showing TFEB nuclear translocation in 
ETR SCs (part of a seminiferous tubule), confirming the IF and IEM results (A,B). S: SC nucleus; L: 
Leydig cell. This was reprinted from Reference [43]. 
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3. Natural Products as Inhibitors of Autophagy in Cancer 
Autophagy is mandatory to maintain cell homeostasis. In healthy cells, this homeo-
static activity provides a strong barrier against oncogenesis. As a result, many oncopro-
teins inhibit and several oncosuppressor proteins promote autophagy. In addition, au-
tophagy might contribute to oncogene-induced cell death or oncogene-induced senes-
cence, which are two fundamental oncosuppressive mechanisms. Additionally, autoph-
agy is necessary for optimal anticancer immunosurveillance. However, autophagy en-
hances the progression of established cancers via multiple mechanisms, and pharmaco-
logical inhibitors of autophagy may have robust antineoplastic effects, at least in certain 
contexts. Enhanced autophagy in the stromal compartment of pancreatic cancers supports 
tumor growth via autophagy-mediated secretion of the nonessential amino acid alanine, 
thus fueling the mitochondrial metabolism of cancer cells and allowing them to thrive in 
an austere microenvironment [8–10]. Therefore, as shown in Figure 3, the enhanced ex-
pression of LC3-II in the stromal cells of ovarian cancer may fuel the growth of cancer 
cells. Natural products have historically been regarded as different doctrines of traditional 
medicine or folk medicine for the management and treatment of a variety of human dis-
eases, including cancer, by inhibiting autophagy pathways [4,44,45]. Several studies have 
shown that the inhibition of autophagy using natural compounds can effectively enhance 
the cancer cell death induced by diverse anticancer drugs. Importantly, the use of natural 
products in the suppression of autophagy can be carried out by the specific targeting of 
various structures in the autophagy pathway (isolation membranes, autophagosomes, au-
tolysosomes and lysosomes), as shown in Figure 1. 
3.1. Class III-PI3K Complex Inhibitors 
Class III PI3K mediates the production of PI3P, a key lipid-signaling molecule that is 
known to be required for autophagosome formation via the recruitment of autophagy 
machinery at the IM (Figure 1). Evidence has confirmed that class III-PI3K inhibitors in-
terfere with the formation of autophagosomes. The main inhibitors for the early stages of 
autophagy, including the mechanism of action (M/A), are given in Table 1. 
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Table 1. Examples of natural materials that modulate autophagy, including chemical structure. 
Target Stage of 
Autophagy 
Natural Product Chemical Structure Derivatives Biological Sources Autophagy-Related M/A Traditional Indications 
Affected Cancer 
Cell Type Tested 
Remarks 
Autophagy inhibitors: Initiation and nucleation stage inhibitors 
Nucleation Wortmannin 
 





 Inhibition of class III 
PI3K activity 




both class I and III PI3K 
[46–49] 










Irreversible, and pan- 






ULK1 suppression and ac-
tivation of mTORC1. 
Highly toxic 
In vitro research 
only 
Interference translocation 












Preclinical studies U937 cells 
Inhibition both of pro-






Lemon balm (Melissa 
officinalis) 
Reduction in LC3-II ex-
pression 
Anti-viral infection 
A wide range of hu-
man cancers 
Precise inhibitory mecha-
nism of cellular enzymes 
remains elusive [58] 
Elongation and fusion stage inhibitors 








(L.) or Vinca rosea 
Depolymerization of 
whole MT network 
Approved cancers 
A wide range of hu-
man cancers 
No protection the entry of 







(L.) or Vinca rosea 
Depolymerization of 




No protection the entry of 






Autumn crocus  
Colchicum autumnale 
Depolarization and inter-
ruption of microtubule 
dynamics 
Gout, Behçet’s disease, 
FMF, swelling 
Lung cancer cells 
Inducer of ROS mediated 
autophagy at clinically 
admissible concentration 
[59] 







South African tree 
Combretum caffrum 
(Combretacae) 
Inhibition of MT polymer-
ization 
- 
CT-26, Caco-2 and 
HT-29 cells 
Vascular disrupting 
agents (VDA) [61–64] 
Elongation N-Acetyl-L-Cysteine 
 
Prodrug of L-cysteine Onion, Allium cepa 
Limiting ROS and block-
ing ATG4 
Chest pain, ALS, Alz-
heimer’s disease 
A wide range of hu-
man cancers 
In specific cases, autoph-





Hop plant Humulus 
lupulus L. 
Inhibition of VCP func-
tion; Up-regulation of p62 
and LC3-II 
Preclinical cancers 
A wide range of hu-
man cancers 
Activation of ER stress by 
suppressing of NF-κB, 
[67] 





Inhibition of LC3 lipida-
tion 
Cardiovascular-related 
disease, Fibrosis Disease 
A wide range of hu-
man cancers 
Induction of autophagy 
by suppressing the mTOR 
pathway [68–73] 






dulea sericea (Willd) 
Inhibition of LC3 lipida-
tion 
Preclinical cancer 
A wide range of hu-
man cancers 
Inhibition of autophagy 
flux by accumulating p62 
[74,75] 




ylic acid antibiotic 
Streptomyces cinna-
monensis 
Na+/H+ ionophore Coccidiosis 
A wide range of hu-
man cancers 
Act as proton exchanger 







ces conglobatus  
Ca2+ ionophore, releases 
Ca2+ from intracellular 
stores 









Inhibition of efflux mecha-
nism of lysosome 
Development of brain 
A wide range of hu-
man cancers 
Low-asparagine diet can 







Seed embryo of Ne-
lumbo nucifera Gaertn 
Impairment of RAB7A re-




A wide range of hu-
man cancers 











Inhibition of lysosomal 
proteolytic activity 
Antiseptics, antidepres-
sants, and antibiotics  
A wide range of hu-
man cancers 
Guttiferone K is another 
active component of the 
plant causes autophagy 
induction [82–86] 
Autolysosomal acidification stage inhibitors 

















A wide range of hu-
man cancers 
Failure to kill intracellular 
mycobacteria in NTM, 
Mycobacterium abscessus in 














A wide range of hu-
man cancers 













matory, antiviral actions 
A wide range of hu-
man cancers 
Induction of autophagy 











A wide range of hu-
man cancers 




Plant Gentiana lutea 
and mycelium of As-
pergillus stellatus de-
rivative 
Blocking autophagic flux 
Approved for schistoso-
miasis 
A wide range of hu-
man cancers 
A blocker of DNA base 
excision repair [94] 
Vacuolar H+-ATPase inhibitors 












High toxicity profile 
Experimental agent 
Universal V-ATPase in-













Antibiotic, Neoplasm Experimental agent 
Universal V-ATPase in-







marine sponges of 
the genera Haliclona 
sp., Xestospongia sp. 





A wide range of hu-
man cancers 
v-ATPase inhibition is 














Approved for range 















Highly toxic and univer-
sal V-ATPase inhibitor 
[103] 
















Potent and specific V-
ATPase inhibitors [103] 









Serine protease inhibitor 
Experimental agent 
(In vitro) 
Agent for analyzing au-






Hexapeptide metabolite Actinomycetes 
Lysosomal Aspartyl pro-




















A wide range of hu-
man cancers 






3, 3′, 4′, 5, 7-pentahy-
droxyflavone 
Many foods, includ-
ing fruits, vegetables 
and beverages 
Induction of FOXO1 and 














Different in fruits 
and vegetables such 
as Cuscuta chinensis 
and Hypericum perfo-
ratum. 





A wide range of hu-
man cancers 
Multipotential neuropro-
tective action in CNS dis-
eases [111] 





Widely distributed in 
fruits and vegetables 
Inhibition of the 
PI3K/AKT/mTOR path-




A wide range of hu-
man cancers 
Inhibition of autophagy 
flux in in the HEKs and 
CSCC [112,113] 
Initiation 





Coffee plant seeds, 
Tea leaves of Camellia 
sinensis 




A wide range of hu-
man cancers 
Amelioration of a variety 
of human diseases includ-





Soybean and other 
legumes, such as 
Vigna angularis 
Inhibition of the PI3K-
AKT signaling pathway 
and N-CoR misfolding; in-





A wide range of hu-
man cancers 
Beneficial agent in treat-









(Curcuma longa L.), 
Curcuma zedoaria 
(Christm). Rosc., and 
Curcuma petiolata 
Increases transcriptional 
activity of TFEB, which in 
turn suppresses mTOR 




Clinical trial for can-
cers 
In specific cases, autoph-





Fruits such as berries, 









A wide range of hu-
man cancers 
Attenuation in cigarette 
smoke-induced autoph-
agy (at higher concentra-
tions) [118,124–126] 





Propolis, honey and 
plants such as Passi-
flora caerulea, Passi-
flora incarnate 
Decrease in LC3-II, Be-




A wide range of hu-
man cancers 












Activation of AMPK, sup-
pression mTOR activity 
Several pharmacological 
actions 
A wide range of hu-
man cancers 
Inhibition of autophagy 
in MCF7 breast cancer 
cells [128–130] 













pertrophy by inhibiting 











ER stress, upregulation of 
LC3-II and Beclin1 
Numerous pharmaco-
logical actions 
A wide range of hu-
man cancers 
Modulation of ER stress 
and autophagy and/or 
apoptosis in a cell-type- 
and context-dependent 
manner [133,134] 




Root bark of mul-
berry tree (Morus alba 
L., Morus nigra L, M. 
australis) 





A wide range of hu-
man cancers 
Inhibition of NF-κB and 





Polyphenolic ketone Mallotus philippinensis 
Inhibition of mTOR sig-
naling and AMPK induc-
tion 
Tapeworm, scabies and 
herpetic ringworm 
A wide range of hu-
man cancers 
Protein kinase C-δ inhibi-
tor [137–139] 






Stem bark of the Pa-
cific yew tree (Taxus 
brevifolia Nutt), bark 
of Pacific Taxus 
chinensis 
Increase LC3-II, ATG5 
and Beclin1 levels 
FDA-approved for meta-
static ovarian cancer 
Lung-, ovarian- and 
breast cancers 
Inhibition of autophagy 
in MCF-7 and SK-BR-3 






Unsaturated tail of to-
cotrienol 
Abundant in rice 
bran oil, palm oil, 
and annatto seeds 
AMPK activation, increas-





A wide range of hu-
man cancers 







Plant, Mirabilis jalapa, 
apple peels 
Increasing LC3-II, ATG5 
and Beclin1 levels, inhibi-














Inhibition of the mTOR 
pathway 
- 
KRAS mutant CRC 
cells 
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Based on their blocking effect on class III PI3K activity, the natural product wortman-
nin [46,47] and its concurrent synthetic compounds, 3-methyladenine (3-MA), KU55933 
and LY294002, are well recognized as early stage autophagy inhibitors in the literature 
[190]. Wortmannin was originally identified as a potent inhibitor of the neutrophil respir-
atory burst and smooth muscle myosin light chain kinase (MLCK) [48]. Later on, it has 
become clear that wortmannin is a more potent inhibitor of the PI3K superfamily than of 
the MLCK. More recently, wortmannin has also been reported to suppress polo-like ki-
nase 1 (PLK1) [191], mTOR [49], DNA-dependent protein kinase (DNA-PK) [192] and 
ataxia–telangiectasia mutated (ATM) [193] at micromolar concentrations [194]. Unlike 3-
MA, wortmannin is a more practical and feasible autophagy inhibitor due to more persis-
tent suppression on class III PI3K, regardless of the nutritional status. While 3-MA, wort-
mannin, and LY294002 have been useful in many contexts to inhibit autophagy and to 
eventually sensitize tumor cells to death, they also target class I PI3Ks. As non-specific 
inhibitors of PI3K, these compounds affect several cell processes and are toxic after long-
term exposure [195]. Moreover, these compounds have been shown to play a role in many 
other cellular processes, including fluid-phase endocytosis and cell migration [196]. Thus, 
these compounds have been unsuitable for clinical applications due to their inherent tox-
icity, poor solubility and low stability [33]. However, nanoparticle (NP)-based drug deliv-
ery of wortmannin reduces its toxicity and increases its solubility [197], and thus NP-
wortmannin acted as a potent radiosensitizer in vitro and in vivo in a mouse xenograft 
model of cancer. This indicates that the administration of wortmannin nanoparticle med-
ications may have clinical applications [197]. Interestingly, a synthetic derivative of wort-
mannin, PX-866 (sonolisib), is a potent pan-isoform inhibitor of PI3K that blocks te-
mozolomide-induced autophagy and promotes apoptosis in glioblastoma cells [50]. Treat-
ment with PX-866, in combination with docetaxel, is well tolerated without evidence of 
cumulative toxicity and controls disease progression in patients with advanced solid tu-
mors. Furthermore, PX-866 was identified as completing several clinical trial evaluations 
(Identifier: NCT01331083, NCT01204099, NCT01252628, and NCT01259869) for the treat-
ment of patients with recurrent or metastatic cancer [51–53]. Several reports have shown 
that cycloheximide is a fast and effective inhibitor of the early stages of autophagy [54,55]. 
However, cycloheximide is generally used only for autophagy inhibition in vitro because 
it is not suitable for human use due to significant toxic side effects, including DNA dam-
age and teratogenesis [55]. 
Petrosaspongiolide M (PSM) exerts inhibitory effects on autophagy in the human his-
tiocytic lymphoma (U937) cells by downregulating Beclin1 levels. As an immunopro-
teasomal inhibitor, PSM binds the active sites in the inner core of proteasome in U937 cells 
and accumulates ubiquitinated proteins, as well as p53, which is a regulator of the cell-
cycle and cell death [56]. In this regard, PSM represents an interesting molecule for the 
modulation of intracellular proteolysis through the dual inhibition of proteasome and au-
tophagy [57]. Epirubicin (EPI) is an anthracycline drug that has been widely used to treat 
bladder cancer. As a topoisomerase-II inhibitor, EPI causes apoptosis in cancer cells by 
inducing DNA damages. However, resistance to EPI becomes a great challenge in treating 
bladder cancer because it induces cytoprotective autophagy in bladder cancer cell lines 
T24 and BIU87 via the activation of JNK-mediated phosphorylation of Bcl-2 and disrup-
tion of the Bcl-2/Beclin1 complex [198]. The green tea derivative tea polyphenol (TP) dis-
plays strong biological effects, including anticancer properties. TP inhibits EPI-induced 
autophagy and promotes EPI-induced apoptosis in human bladder cancer cells [198]. 
Harmine analogues have long been considered to be anticancer agents due to their re-
ported anti-proliferative activity. While harmines seem to cause DNA damage and inhib-
its cellular enzymes, the precise mechanism of action of harmines remains elusive. It has 
been found that N2-benzyl and N9-arylated alkyl, which are analogues of harmine, 
strongly inhibit the growth of cancer cells that originate from the breast, lung, bone and 
pancreas, but not that of normal fibroblasts via the induction of apoptosis and inhibition 
of autophagy by reducing the conversion efficiency of LC3-I to LC3-II [58]. 
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3.2. IM Elongation and Enclosure Stage Inhibitors 
Since MTs have a major role in autophagy pathways in non-mitotic cells, MTs may 
be effective targets in cancer cell death. The MT targeting agents (MTAs) of natural drugs 
have shown potential therapeutic benefits in cancers [59]. Many natural agents and/or 
their MTA analogues may bind to the tubulin and alter the assembly properties used in 
tumors by inhibiting mitosis. Based on the role of the MT network in autophagy, pharma-
cological MTAs are classified into two main groups. The first group is microtubule-desta-
bilizing agents (or antipolymerization drugs), such as the vinca alkaloids (vinblastine, vin-
cristine, vinorelbine, vindesine and vinflunine), colchicine, cryptophycins, halichondrins, 
estramustine and combretastatins, which are used clinically or are under clinical investi-
gation for the treatment of cancer [59]. The second group is MT-stabilizing agents, which 
stimulate MT polymerization, with examples including paclitaxel (Taxol), docetaxel (Tax-
otere), the epothilones, and discodermolide. 
Vinca alkaloids are considered “wonder drugs” for fighting cancer [13,60]. For exam-
ple, they are used in the treatment of childhood hematologic malignancies (leukemia). 
Vinca alkaloids vinblastine or vincristine are able to depolymerize the whole MT network 
(both acetylated and non-acetylated forms) and reduce the conversion efficiency of LC3-I 
to LC3-II. These alkaloids contribute to their anticancer activity by preventing autopha-
gosome formation and maturation [60]. At higher concentrations, vinblastin reduces the 
autophagic marker p62 and completely inhibits the merging of autophagosomes with ly-
sosomes [60]. 
Colchicine was approved by the Food and Drug Administration (FDA) in 2009 for 
the treatment of gout attacks and familial Mediterranean fever. Previous studies have 
shown that colchicine induces autophagy and senescence in lung cancer cells at a clinically 
acceptable level. However, extensive research studies suggest that it prevents autophago-
some formation by inhibiting MT polymerization as a tubulin binder and thus acts as mi-
totic spindle poison in cells. Combretastatins exhibit cytotoxic properties and inhibit tu-
bulin polymerization in cancer cells in vitro [60]. Combretastatin A-4 (CA-4, also known 
as fosbretabulin), the most potent member of this family, has a great effect in antitumor 
therapy and has entered several clinical trials for solid tumors. CA-4 phosphate (CA-4P), 
a water-soluble prodrug of CA-4, has also progressed into clinical trials for the treatment 
of solid tumors (Table 2). Since CA-4 has a high affinity to tubulin and destabilizes the 
tubulin polymers of the cytoskeleton, it is also used as an angiogenesis inhibitor and a 
vascular disrupting agent [60,61]. Some reports have shown that CA-4 induces prosur-
vival autophagy in both human osteosarcoma [62] and adenocarcinoma cells [63]. How-
ever, evidence has indicated that the suppression of autophagy has been suggested to po-
tentially enhance the therapeutic efficacy of CA-4 [63,64]. 
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Table 2. Ongoing and completed clinical trials with natural products for the treatment of cancer (the structures of these 
products are shown in Table 1). 
Treatment Strategy 
Disease/Conditions Phase/Status Identifier Sponsor 
Inhibitor Other Intervention 
PX-866  
Docetaxel NSCLC; SCC 1/2/C NCT01204099 Cascadian Therapeutics Inc. 
- Advanced Solid Tumors 1/C NCT00726583 Cascadian Therapeutics Inc. 
Cetuximab Colorectal Carcinoma 1/2/C NCT01252628 Cascadian Therapeutics Inc 
- Glioblastoma 2/C NCT01259869 NCIC Clinical Trials Group 
Vinblastine 
Sirolimus CNS Tumors 1/C NCT01135563 The Hospital for Sick Children 
CyP, Cape, Nivolumab Childhood Lymphoma 1/2/R NCT03585465 Centre Oscar Lambret 
Selumetinib Sulfate  Astrocytoma 3/R NCT04576117 National Cancer Institute (NCI) 
Bevacizumab Low Grade Glioma 2/R NCT02840409 The Hospital for Sick Children 
Nivolumab Hodgkin Lymphoma 2/R NCT03580408 Lymphoma Academic Research Org. 
Dox, Bleomycin, Nivolumab Hodgkin Lymphoma 1/2/R NCT03033914 Memorial Sloan Kettering Cancer Center 
Dox, Bleomycin, Dacarbazine Hodgkin Lymphoma 3/R NCT03159897 Fondazione Italiana Linfomi ONLUS 
Cisplatin, TMZ Skin Cancer 2/C NCT00885534 Memorial Sloan Kettering Cancer Center 
Vincristine 
Cytarabine R-EphB4-HSA Myelodysplastic neoplasm 1/R NCT03519984 University of Southern California 
CyP Vinorelbine Actino D Rhabdomyosarcoma 2/R NCT04388839 H. Lee Moffitt Cancer Center 
Venetoclax B ALL 1/2/R NCT03504644 ECOG-ACRIN Cancer Research Group 
Inotuzumab Ozogamicin  Recurrent B ALL 1/2/R NCT03851081 Roswell Park Cancer Institute 
TMZ Ewing Sarcoma 2/R NCT03359005 Peking University People’s Hospital 
Camrelizumab, Dacarbazine Hodgkin Lymphoma 2/R NCT04067037 Henan Cancer Hospital 
Carboplatin Irinotecan Pilocytic Astrocytoma  1/2/R NCT01837862 Julie Krystal 
Etoposide, Dox, CyP Recurrent B ALL 1/R NCT03991884 University of Washington 
Pegaspargase, CyP, etoposide NK/T Cell Lymphoma 2/R NCT04484506 Peking University 
Melphalan, etoposide Retinoblastoma 2/3/R NCT04681417 Institut Curie 
Brentuximab, Dox Rituximab Hodgkin Lymphoma 2/R NCT02398240 Mitchell Cairo 
Colchicine 
- Hepatocellular Carcinoma 2/R NCT04264260 Kaohsiung Medical University  
- Hepatocellular Carcinoma 2/C NCT01935700 Kaohsiung Medical University 
CA-4P 
Paclitaxel, Carboplatin Cancer, Tumor 2/C NCT00113438 Mateon Therapeutics 
Bevacizumab (Avastin) Tumors 1/C NCT00395434 Mateon Therapeutics 
CA-2P - Neoplasm Metastasis 1/C NCT00960557 Mateon Therapeutics 
Fosbretabulin 
- Head and Neck Cancer 2/C NCT00060242 Case Comprehensive Cancer Center 
Paclitaxel, Bevacizumab Tumors 2/C NCT00653939 Mateon Therapeutics 
- Adult Solid Tumor 1/C NCT00003698 University of Glasgow 
- Adult Solid Tumor 1/C NCT00003768 Case Comprehensive Cancer Center 
- Neuroendocrine Tumors 2/C NCT02132468 Mateon Therapeutics 
- Neuroendocrine Tumors 2/C NCT02279602 Mateon Therapeutics 
NAC 
- Breast Cancer 1/C NCT01878695 Thomas Jefferson University 
- Ovarian Cancer 1/2/NR NCT04520139 University of California, Irvine 
Simethicone Stomach Neoplasms 4/C NCT01653171 Pontificia Universidad Catolica de Chile 
- Bronchial Carcinoma 4/C NCT00196885 German Cancer Research Center 
 Neurofibromatosis 1 2/R NCT04481048 
Children’s Hospital Med Center, Cincin-
nati 
Sodium thiosulfate Esophageal Carcinoma R NCT04764643 Xijing Hospital of Digestive Diseases 
Azithromycin 
Hydroxychloroquine Cancer and COVID 19 2/R NCT04341207 
Gustave Roussy, Cancer Campus, Grand 
Paris 
- Adenomatous Polyposis 4/NR NCT04454151 Tel-Aviv Sourasky Medical Center 
Cefixime  Cervical Papilloma U NCT02830230 Tata Memorial Hospital 
Clarithromycin 
Abemaciclib Neoplasm Metastasis 1/C NCT02117648 Eli Lilly and Company 
Prasterone  Multiple Myeloma 2/C NCT00006219 Mayo Clinic 
Lenalidomide Dexame-
thasone 
Multiple Myeloma 2/R NCT04063189 The First Hospital of Jilin University 
Pomalidomide Dexame-
thasone 
Multiple Myeloma 2/NR NCT04843579 




Multiple Myeloma 2/NR NCT04302324 




Plasma Cell Myeloma 2/C NCT00445692 Fred Hutchinson Cancer Research Center 
Thalidomide dexamethasone Multiple Myeloma 2/C NCT00182663 Fred Hutchinson Cancer Research Center 




Multiple Myeloma 2/C NCT01159574 




Multiple Myeloma 3/R NCT04287660 First Affiliated Hospital of Soochow Uni 
Omeprazole, Amoxicillin, Gastric MALT Lymphoma NA/C NCT00327132 
National Health Research Institutes, Tai-
wan 
Amoxicillin, Metronidazole B-cell Lymphoma 2/R NCT02388581 
National Health Research Institutes, Tai-
wan 
Ciprofloxacin, lansoprazole CLL 2/C NCT01279252 King’s College Hospital NHS Trust 
Amoxicillin, Metronidazole Lymphoma 2/C NCT00002682 M.D. Anderson Cancer Center 
Bismuth subcitrate Amoxicil-
lin 
Lymphoma 2/C NCT00003151 EORTC 
Lucanthone TMZ, Radiation Glioblastoma Multiforme 2/T NCT01587144 Spectrum Pharmaceuticals, Inc 
Dox 
L-DOS47 Pancreas Cancer 1/2/R NCT04203641 Helix BioPharma Corporation 
Irinotecan, 5-fluorouracil Gastric Cancer 2/R NCT04358341 Sixth Affiliated Hospital, Sun Yat-sen Uni 
Fludarabine Ovarian Cancer 2/R NCT03335241 Sun Yat-sen University 
CyP Breast Cancer Patients - NCT04654195 Damanhour University 
PD-1 Bladder Cancer 2/R NCT04101812 
Tianjin Medical University Second Hospi-
tal 
- Breast Cancer 2/R NCT03933319 Chinese Academy of Medical Sciences 
Trastuzumab, paclitaxel Breast Cancer 1/2/R NCT03994107 Peking Union Medical College 
Bortezomib Serous Carcinoma 2/R NCT03509246 Seoul National University Hospital 
Bevacizumab, Pembroli-
zumab 
Ovarian Cancer 1/R NCT03596281 
Gustave Roussy, Cancer Campus, Grand 
Paris 
CyP, Atezolizumab Breast Cancer 2/R NCT03164993 Oslo University Hospital 
Rapamycin 
- Breast Cancer 2/R NCT02642094 LuZhe Sun 
- Bladder Cancer 2/R NCT04375813 Emtora Biosciences 
- Pancreatic Cancer 1/2/R NCT03662412 Zhejiang University 
Nivolumab Ewing Sarcoma 1/2/R NCT03190174 Sarcoma Oncology Research Center, LLC 
- Refractory Solid Tumors 4/R NCT02688881 Samsung Medical Center 
Quercetin 
Fisetin, Dasatinib Frailty, Childhood Cancer 2/NR NCT04733534 St. Jude Children’s Research Hospital 
- Squamous Cell Carcinoma 2/R NCT03476330 
Children’s Hospital Med Center, Cincin-
nati 
Green tea extract Prostate Cancer 1/ANR NCT01912820 Jonsson Comprehensive Cancer Center 
EGCG 
- Colon Cancer 1/R NCT02891538 University of Texas Health Science Center 
- Breast Neoplasms 2/U NCT02580279 Shandong Cancer Hospital and Institute 
- Prostate Cancer 2/C NCT00676780 Louisiana State University Health Sciences 




Uterine Fibroids 1/R NCT04177693 Yale University 
Genistein 
Sugar pill Bladder Cancer 2/R NCT01489813 Emory University 
Gemcitabine Breast Cancer 2/C NCT00244933 Barbara Ann Karmanos Cancer Institute 
Decitabine NSCLC 1/2/C NCT01628471 Uman Pharma 
- Breast Cancer 2/C NCT00290758 National Cancer Institute (NCI) 
Erlotinib HCl, gemcitabine 
HCl 
Pancreatic Cancer 2/C NCT00376948 Barbara Ann Karmanos Cancer Institute 
Curcumin 
- Prostate Cancer  3/R NCT03769766 
University of Texas Southwestern Med 
Center 
- Breast Cancer 1/R NCT03980509 Medical University of South Carolina 
- Breast Cancer  R NCT03865992 City of Hope Medical Center 
- Head and Neck Cancer 2/R NCT04208334  Phramongkutklao College Hospital 
- Prostate Cancer  NCT02064673  
University of Texas Southwestern Med 
Center 
Pembrolizumab, Vit D, CyP Endometrial Cancer  NCT03192059 University Hospital, Ghent 
Resveratrol 
Metformin PCOS 2/NR NCT04867252 Khyber Medical University Peshawar 
Simvastatin PCOS 4/U NCT02766803 Poznan University of Medical Sciences 




2/U NCT03253913 University of Cincinnati 
Fisetin Dasatinib, Quercetin Childhood Cancer 2/NR NCT04733534 St. Jude Children’s Research Hospital 
β-elemene EGFR-TKIs NSCLC 2/U NCT03123484 China Medical University 
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- Astrocytoma, Glioblastoma 3/R NCT02629757 Sun Yat-sen University 
Ursolic Acid Curcumin Prostate Cancer 1/NR NCT04403568 University of Texas Health Science Center 
Tocotrienol Bevacizumab Ovarian Cancer Recurrent 3/R NCT04175470 Vejle Hospital 
Paclitaxel 
- Breast Cancer 2/NR NCT03959397 Jilin University 
Apatinib, Camrelizumab Advanced Gastric Cancer 1/2/NR NCT04286711 China Medical University 
Carboplatin Prostate Cancer 1/2/NR NCT04148885 Shanghai Jiao Tong University 
Pembrolizumab Breast Cancer 2/NR NCT03841747 Queen Mary University of London 
- Breast Cancer 2/NR NCT04194684 Chinese Academy of Medical Sciences 
Pyrotinib Breast Cancer 2/NR NCT04659499 Peking Union Medical College Hospital 
Oxaliplatin, Cape Gastric Cancer 1/NR NCT03977220 Shanghai Zhongshan Hospital 
Mipsagargin  G-202, Tapsigargin pro-drug Advanced Solid Tumors 1/C NCT01056029 GenSpera, Inc. 
Betulinic acid - 
Dysplastic Nevus Syn-
drome 
1/2/S NCT00346502 University of Illinois at Chicago 
* CRLX101 Enzalutamide Prostate Neoplasms 2/R NCT03531827 National Cancer Institute (NCI) 
* EP0057 
Olaparib Urothelial Carcinoma 1/2/R NCT02769962 National Cancer Institute (NCI) 
Olaparib tablets Ovarian Cancer 2/R NCT04669002 Ellipses Pharma 
Camptothecin 
- Adult Solid Tumor 1/C NCT00059917 Memorial Sloan Kettering Cancer Center 
- Solid Tumor 1/2/C NCT00333502 NewLink Genetics Corporation 
Berberine HCl 
- Colorectal Adenomas 2/3/R NCT03333265 xiaohua li 
- Colorectal Adenoma 2/3/C NCT02226185 Shanghai Jiao Tong University 
Gefitinib Lung Adenocarcinoma 2/U NCT03486496 Fujian Cancer Hospital 
- Colorectal Adenomas 2/3/U NCT03281096 xiaohua li 
Thymoquinone 
- Premalignant Lesion 2/C NCT03208790 Cairo University 
Metformin PCOS 2/3/C NCT04852510 Saudi German Hospital—Madinah 
R-(–)-gossypol 
- Adult Glioblastoma 2/C NCT00540722 National Cancer Institute (NCI) 
- Adrenocortical Carcinoma 2/C NCT00848016 National Cancer Institute (NCI) 
TMZ  Brain and CNS Tumors 1/C NCT00390403 Sidney Kimmel Com Cancer Center 
Paclitaxel, carboplatin  Follicular Lymphoma 1/C NCT00891072 National Cancer Institute (NCI) 
 
Non-small Cell Lung 
Cancer 
3/U NCT01977209 Third Military Medical University 
Cisplatin, etoposide Small Cell Lung Cancer 1/C NCT00544596 National Cancer Institute (NCI) 
Trichostatin A - Hematologic Malignancies 1/U NCT03838926 Vanda Pharmaceuticals 
Antroquinonol 
- Pancreatic Neoplasm 1/2/R NCT03310632 Golden Biotechnology Corporation 
- 
Non-small Cell Lung 
Cancer 
1/C NCT01134016 Golden Biotechnology Corporation 
- 
Non-small Cell Lung 
Cancer 
2/C NCT02047344 Golden Biotechnology Corporation 
- Acute Myeloid Leukemia 2/C NCT03823352 Golden Biotechnology Corporation 
EPA 
AMR101  Colorectal Adenoma 1/2/R NCT04216251 Massachusetts General Hospital 
AMR101 (VASCEPA) Colon Cancer 2/R NCT03661047 Mingyang Song 
EPA-FFA - Adenomatous Polyposis 3/R NCT03806426 S.L.A. Pharma AG 
EPA Tyrosine kinase inhibitor Chronic Myeloid Leukemia 1/2/R NCT04006847 Milton S. Hershey Medical Center 
Icosapent Ethyl - Liver Metastasis 3/R NCT03428477 Mark A Hull, PhD FRCP 
DHA 
- Breast Cancer 2/R NCT03831178 AHS Cancer Control Alberta 
EPA NSCLC NR NCT04175769 AHS Cancer Control Alberta 
EPA Lung Cancer 2/3/U NCT01048970 National Institute of Cancerología 
Paclitaxel Pancreatic Cancer 2/U NCT00024375 Theradex 
Paclitaxel Prostate Cancer 2/U NCT00024414 Theradex 
Paclitaxel Colorectal Cancer 2/U NCT00024401 Theradex 
ATRA 
Lupron, 5-Azacitidine Prostatic Neoplasms 2/R NCT03572387 Icahn School of Medicine at Mount Sinai 
Anastrozole Breast Neoplasm 2/R NCT04113863 Mario Negri Inst for Pharm Research 
- Leukemia R NCT01064557 Gruppo Italiano Malattie  
VEGFR inhibitor Adenoid Cystic Carcinoma 2/R NCT04433169 Shanghai Jiao Tong University 
Tranylcypromine, cytarabine Acute Myeloid Leukemia 1/2/R NCT02717884 Michael Luebbert 
- APL 2/R NCT01064570 Gruppo Italiano Malattie 
Arsenic Trioxide, Mylotarg APL 2/R NCT04793919 Associazione Italiana Ematologia 
Cytarabine, Arsenic Trioxide AML 1/2/R NCT03031249 
Institute of Hematology and Blood Dis-
eases 
* CRLX101 is a nanoparticle-drug conjugate of CPT molecules; EP0057, a Nanoparticle CPT. 
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As an antioxidant agent, N-acetyl cysteine (NAC) effectively abolishes oxidative 
stress markers, such as intracellular reactive oxygen species (ROS) [65], and alters the cel-
lular redox status. NAC therefore plays an important role in triggering apoptosis and in-
hibiting the autophagy induced by starvation, trehalose and recombinant human arginase 
(rhArg) in COS-7 and HeLa cells. NAC also induces apoptosis in colon carcinoma cells by 
increasing the pro-apoptotic Bax levels and by increasing susceptibility to the chemother-
apeutic agent 5-fluorouracil (5-FU) [66]. 
The natural valosin inhibitor containing protein (VCP or p97) xanthohumol (XN) has 
been considered for its potentially beneficial effects in HeLa cells, including the inhibition 
of diacylglycerol acyltransferase, induction of apoptosis, as well as the inhibition of au-
tophagy via the upregulation of p62 and LC3-II [67]. 
To date, over 10 different salvianolic acids have been identified and referred to: sal-
vianolic acid A, B, C, D, E, F, G, etc. Salvianolic acid A (Sal A) and salvianolic acid B (Sal 
B) are the most abundant compounds among salvianolic acids. Both in vitro and in vivo, 
most of the salvianolic acids showed anti-inflammatory and antioxidative effects [68]. 
Some studies predict that Sal A and Sal B will have therapeutic effects on breast cancer, 
lung cancer and liver cancer. Sal A reverses the resistance of circulating cancer cells (CCC) 
in breast cancer MCF-7/PTX cells to paclitaxel [69,70]. Sal A potentially reduces A549 lung 
cancer cell growth, and promotes apoptosis by enhancing the expression of phosphatase 
and the tensin homolog deleted on chromosome 10 (PTEN) and localized on the cytoplas-
mic membrane, which in turn inhibits PI3K signaling. Sal A inhibits the growth of mouse 
lung cancer cells by inhibiting the expression of c-myc and JNK [68]. Sal B, combined with 
other compounds, inhibits migration, invasion and the epithelial–mesenchymal transition 
(EMT) process of A549 cells by PTEN/PI3K/protein kinase B (PKB or AKT) [71]. Addition-
ally, Sal B inhibits the proliferation of breast cancer cells and promotes their apoptosis 
[68]. Sal B reduces the incidence of squamous cell carcinoma (SCC) by inhibiting angio-
genesis and decreasing the expression of hypoxia-inducible factor 1α (HIF-1α) and vascu-
lar endothelial growth factor (VEGF) [68]. Sal B exerts some inhibitive effects on lung can-
cer [72] in vivo. Sal B could activate apoptosis in human hepatocellular carcinoma (HCC) 
through the mitochondrial pathway [73]. Interestingly, Sal B induces autophagy in both 
hepatoma cells and colorectal cancer (CRC) cell lines. The Sal B-induced autophagy, which 
is mediated by the AKT/mTOR signaling pathway, can play a pro-apoptotic role in cancer 
cells [73]. It is also reported that Sal B inhibits the early stages of autophagy and interferes 
with the development of autophagosome via the inhibition of LC3 lipidation and by 
blocking the elongation of IM [68,73]. 
Deguelin effectively inhibits autophagy in several types of cancer, including pancre-
atic cancer, by blocking LC3 lipidation. Deguelin induces incomplete autophagy in pan-
creatic cancer cells by inhibiting autophagy flux, as evidenced by the impairment of au-
tophagosome maturation and the subsequent accumulation of LC3-II and p62 in dose- 
and time-dependent manners [74]. Doxorubicin-induced autophagy (Dox) plays a pro-
survival role in pancreatic cancer cells; thus, the pharmacological inhibition of autophagy 
by QC or the silence of ATG5 enhances Dox-induced cancer cell death. Similarly, 
deguelin’s inhibition of autophagy has also chemosensitized pancreatic cancer cell lines 
to Dox [74]. However, a previous study showed that deguelin may induce both apoptosis 
and autophagy in cultured head and neck SCCs. This is mediated by the inhibition of AKT 
signaling, the downregulation of survivin and cycline-dependent kinase 4 (Cdk4) expres-
sion, as well as the disruption of their association with heat shock protein 90 (Hsp-90) [75]. 
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3.3. Docking and Fusion Stage Inhibitors 
Polyether ionophores, such as monensin and nigericin, are produced by Streptomy-
ces species and are potent antimicrobial and anticancer agents that belong to a large class 
of naturally occurring polyketides [76]. A number of studies have revealed that monensin 
and nigericin have been linked to autophagy and cell death via the interference from the 
fusion of autophagosome and lysosome, and thus blocks the maturation of the autophagic 
process. These two compounds block autophagic flux, resulting in the accumulation of 
autophagy flux markers LC3-II and p62, along with the cleavage of caspase-3, caspase-9 
and poly(ADP-ribose) polymerase 1 (PARP-1), which is a hallmark of caspase-dependent 
apoptosis [77,78]. In addition, another polyether antibiotic, salinomycin, is reported to in-
hibit autophagic flux in several cancer cell lines [199]. 
Asparagine-rich foods include dairy products, whey, beef, poultry, eggs, fish, sea-
food, asparagus, potatoes, legumes, nuts, seeds, soy, and whole grains. Low asparagine-
containing foods mostly include fruits and vegetables, which can slow down breast cancer 
metastasis [79]. Mice harboring primary 4T1 mammary tumors treated with L-asparagi-
nase or fed with a low-asparagine diet experienced a decrease in metastases with no effect 
on primary tumor growth. This can be attributed to blockage of the fusion of autophago-
somes with lysosomes and the suppression of lysosomal functions [79]. Additionally, L-
asparaginase has been reported to be an important drug for the treatment of acute lym-
phoblastic leukemia (ALL) cells in the last few decades [80]. Contradictory reports indi-
cate that L-asparaginase catalyzes the conversion of L-asparagine to aspartic acid and am-
monia, resulting in the deprivation of circulating asparagine. This leads to metabolic 
stress, as evidenced by the inhibition of both glycolysis and oxidative phosphorylation, 
and the activation of autophagy in ALL cells [81]. 
Liensinine suppresses autophagic degradation by blocking autophagosome–lyso-
some fusion and the subsequent accumulation of autophagosomes in breast cancer cells. 
While the inhibitory effect on autophagy is similar to CQ and Baf A1, liensinine’s blockage 
of autophagosome–lysosome fusion differs from these inhibitors. CQ and Baf A1 cause 
alkalinized lysosomal pH, suppress the fusion process, and impair the action of lysosomal 
hydrolases, whereas lysosomal pH is unaffected in response to liensinine treatment. Thus, 
lysosomal pH may not be necessary to inhibit autophagosome–lysosome fusion by 
liensinine [200]. Interestingly, liensinine interferes with the recruitment of the small bind-
ing protein GTP RAB7A in lysosomes, but not in autophagosomes, and suppresses the 
transport of endocytic cathepsins to lysosomes and finally stops autophagosome–lyso-
some fusion. Additionally, the combination of liensinine and Dox causes the synergistic 
inhibition of the viability and induction of death in breast cancer cells due to altering au-
tophagy/mitophagy by liensinine [200]. A recent and contradictory study found that the 
bisbenzylisoquinoline alkaloids neferine, liensinine and isoliensinine inhibit cell growth 
and exhibit significant anti-migration activities in prostate cancer cells. They induce apop-
tosis and autophagy by activating cleaved caspase-9, cleaved PARP, Bax, and LC3-II, but 
reduced the expression of Bcl-2 and PARP proteins in LNCaP cells in short-term treat-
ments (24 h) [201]. 
Oblongifoline C (OC) and guttiferone K (GUTK) are the major active components of 
the Garcinia yunnanensis Hu fruit with anticancer activities, but they act through various 
mechanisms [82]. OC promotes apoptosis and inhibits autophagy and cancer metastasis 
[83,84]. Similarly, GUTK activates apoptosis, arrests the cell-cycle, and promotes autoph-
agy [85,86]. However, OC and GUTK show synergistic inhibition on colorectal cancer 
(CRC) HCT116 cells. Moreover, the combination of OC and GUTK markedly increases the 
cleavage of casapse-3, enhances cellular ROS production and upregulates JNK protein 
phosphorylation, resulting in autophagy initiation. OC acts as a powerful autophagic flux 
inhibitor by blocking autophagosome–lysosome fusion and increases the pH in acid com-
partments. In addition, OC inhibits lysosomal proteolytic activity and downregulates ly-
sosomal cathepsins. Importantly, OC efficiently sensitizes nutrient-deprived cancer cells 
to caspase 3-dependent apoptosis in vitro [82]. 
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3.4. Late-Stage Disruptors 
Currently, most of the natural compounds are currently used to inhibit autophagy at 
a late phase of autophagy. For instance, lysosomotropic agents (QC), vacuolar-type 
ATPase inhibitors (V-ATPase) (Baf A1) and lysosomal-type protease inhibitors (pepstatin 
A) all interfere with the final steps of the autophagy pathway. These compounds inhibit 
the degradation of autolysosome by lysosomal enzymes, leading to cytoplasmic accumu-
lation, which may be toxic to cells. Since lysosomes are involved in many biological pro-
cesses besides autophagy (e.g., endocytosis), these molecules have multiple off-target ef-
fects. 
3.4.1. Acidification Stage Inhibitors 
The quinine extracted from the Cinchona bark, and its synthetic analogue CQ (orgin-
allyt used as antimalarial agents), are repurposed for cancer treatment. Thus, these drugs, 
including the antimalarial quinine, CQ, and its derivatives, block the acidification pro-
cesses of autolysosome and lysosomes in cancer cells, resulting in a reduction in au-
tophagic flux and cell death [202]. 
As autophagy plays an essential role in effective cellular response in host defense 
against mycobacterial NTM infections, the use of autophagy blockers, such as azithromy-
cin in patients with chronic inflammatory lung diseases, may result in highly pathogenic 
and fatal infections [87]. Therapeutic doses of azithromycin suppress the clearance of au-
tophagosomes by altering lysosomal acidification and autophagic degradation in macro-
phages, resulting in a failure to kill intracellular mycobacteria and the persistence of lung 
infections [87]. Clarithromycin strongly attenuates the late stages of the autophagy pro-
cess in myeloma cells by halting the fusion of autophagosomes with lysosomes and alter-
ing lysosomal acidification, causing the induction of cell death [88]. 
Matrin shows inhibitory effects on proliferation and metastasis, and causes apoptosis 
in a variety of malignant cells, e.g., C6 glioma cells. As an autophagy inhibitor, matrine 
elevates pH values in endosomes/lysosomes, which in turn inhibits trafficking and lyso-
somal proteases in human gastric cancer cells [89]. Recent contradictory evidence has 
shown that matrine induces autophagy in human hepatoma cells with inactive p53 by the 
induction of the AMPK signaling pathway [90]. Martine-derived MASM, a potent deriv-
ative of matrine, possesses potency against cancer cells by inducing autophagy and apop-
tosis through ROS-mediated PI3K/AKT/mTOR and the extracellular signal-regulated ki-
nase1/2 (ERK1/2)/p38 signaling pathway in epithelial cancer cell lines [91]. Thus, the ac-
tion of matrine is cell-specific and signaling pathway-dependent. 
Elaiophylin acts as an autophagy inhibitor because it disrupts lysosomal degrada-
tion. It blocks autophagic flux in the late stages of autophagy in ovarian carcinoma cells. 
Elaiophylin usage could promote a substantial accumulation of autophagosomes [92]. Ad-
ditionally, elaiophylin abrogates the maturation of cathepsins B and D and induces sub-
sequent lysosomal membrane permeabilization (LMP). Elaiophylin decreases cell viabil-
ity and induces cell death via the inhibition of autophagy and sensitizes the antitumor 
effect to cisplatin in vitro. Administration of elaiophylin (dose 2 mg/kg) displays a signif-
icant antitumor effect without toxicity [92]. Another report suggests that elaiophylin ex-
erts anti-myeloma activity by blocking autophagy flux, inducing apoptosis and arresting 
proliferation in multiple myeloma cells [93]. 
An anti-schistosome agent, lucanthone, impairs autophagy by inducing the accumu-
lation of p62 and disrupting lysosomal functioning. In addition, lucanthone stimulates 
apoptosis via cathepsin D accumulation and potentiates the histone deacetylase inhibitor 
and vorinostat-mediated cell death [94]. Lucanthone, in association with chemotherapeu-
tic agents, has already reached clinical trials (Table 2) and is currently in phase II clinical 
trials for glioblastoma multiforme. 
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3.4.2. Vacuolar-Type H+-ATPase (V-ATPase) Inhibitors 
V-ATPase is found in the membranes of many organelles, including lysosomes, en-
dosomes and secretory vesicles, where they play a variety of vital roles in many cellular 
processes, and its dysregulation leads to the maintenance of the acidic milieu, thus caus-
ing several diseases, such as osteoporosis and cancer [203]. 
Macrolide antibiotics bafilomycins A1, B1, D, F, G, H, I and J are potent autophagy 
inhibitors that function via the induction of autophagosomes accumulation. Baf A1 is con-
sidered to be a selective prototypical V-ATPase inhibitor at low nanomolar concentrations 
and is therefore often used (Baf A1 clamp assay) to block late autophagic flux [95]. Baf A1 
may also target early stages of autophagy by activating mTOR signaling, thus disassoci-
ating the Beclin1-class III complex and inhibiting autolysosomal formation [96]. Thus, Baf 
A1 prevents activation of lysosomal enzymes via blocking its acidification process [97]. In 
addition, Baf A1 induces the binding of Beclin1 to Bcl-2, which further inhibits autophagy 
and promotes apoptotic cell death [96]. Baf A1 also targets mitochondria and induces 
caspase-independent apoptosis by inducing the translocation of apoptosis-inducing fac-
tors from mitochondria to the nucleus [96]. Another selective V-ATPase inhibitor, 
concanamycin-A, also increases the accumulation of autophagosomes [98]. Concanamy-
cin A shows significant global toxicity due to the inhibition of the V-ATPase in several 
tissues. It has been reported that manzamine A has shown anticancer activity against pan-
creatic cancer cells through the inhibition of V-ATPase and autophagy through the accu-
mulation of lysosomes/autolysosomes [99]. For example, manzamine A is active against 
AsPC-1 pancreatic adenocarcinoma cells by reducing cell dissociation, abrogating cell mi-
gration, and sensitizing cells to apoptosis [100]. 
Dox delivers antitumoral activity in two basic ways: through interference with DNA 
synthesis and through the induction of its damage [101]. Dox also blocks autophagic flux 
by impairing lysosome acidification through the suppression of V-ATPase activity and 
lysosomal function. Despite its highly beneficial effects against cancer, its clinical uses are 
limited by its severe side effects, such as life-threatening cardiotoxicity, particularly in 
children with cancer. Since intracellular Ca2+ signaling has been reported to play an im-
portant role in the regulation of autophagy, Dox causes the significant abnormal accumu-
lation of cytosolic Ca2+ in human cardiac progenitor/stem cells and causes cardiotoxicity 
[102]. Another natural V-ATPase inhibitor, cleistanthin A, has shown cytotoxicity in sev-
eral tumor cell lines. Archazolid, another well-investigated V-ATPase inhibitor, reduces 
protease activity, such as B-cathepsin in vitro and in vivo [103]. 
3.4.3. Lysosomal Hydrolytic Enzyme Inhibitors 
Leupeptin impairs amphisome–lysosome fusion and suppresses cathepsin B, H and 
L [104]. Leupeptin also inhibits reversible trypsin-like serine proteases and most cysteine 
proteases (including trypsin, papain, cathepsin B and calpain) [103]. Pepstatin A is an in-
hibitor of acid proteases (aspartyl peptidases). It forms a 1:1 complex with proteases such 
as pepsin, renin, cathepsin D, bovine chymosin, and protease B [105]. 
4. Natural Products as Inducers of Autophagy in Cancer 
In the following section, the main natural products are found to activate autophagy 
(Table 1) and consequently modulate cancer cells in various models. The molecular targets 
(where known) for these mammalian cells are shown in Figure 1. 
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4.1. Initiation Stage Activators: mTOR Inhibitors 
Caloric restriction (CR) or fasting is one natural and effective phenomenon that in-
duces autophagy, as it activates multiple regulatory pathways. For example, CR results in 
the inhibition of mTORC1 and the activation of AMPK, which in turn activates the au-
tophagy-promoting ULK1 complex (Figure 1) [106]. Furthermore, CR stimulates sirtuin 1 
(SIRT1), which deacetylates and thereby activates essential autophagic proteins [106]. 
While the inhibitor mTOR rapamycin (sirolimus) is known to be a powerful autoph-
agy inducer that extends the lifespan of various organisms, from flies to mammals [106–
108], it has serious adverse effects, including insulin resistance [106]. Most of these side 
effects have been attributed to the chronic inhibition of mTORC2 [204]. Consequently, 
considerable effort has been devoted to discovering specific mTORC1 inhibitors, such as 
semi-synthetic analogues of rapamycin (known as rapalogs), including temsirolimus, 
everolimus, deforolimus, zotarolimus, biolimus, WYE-592 and ILS-920 [205], which have 
fewer side effects. These rapalogs are allosteric selective inhibitors of mTORC1 that affect 
downstream targets, including the activation of autophagy [206]. However, their efficacy 
in inhibiting tumor growth is limited due to the lack of inhibition of mTORC2 and other 
compensatory signaling pathways that promote cell survival [206]. Mechanistically, ra-
pamycin is an allosteric inhibitor of mTOR and only suppresses part of the mTORC1 func-
tion, whereas both PP242 and Torin1 are catalytic inhibitors that are able to completely 
suppress both mTORC1 and mTORC2 via binding to ATP-binding sites [206]. 
4.2. Polyphenolic Compounds 
Polyphenolic compounds are the most common bioactive secondary plant metabo-
lites that are present in fruits, vegetables, seeds, and others, and they have a wide range 
of activities in the prevention and treatment of various diseases, including cancers [207]. 
Several of the beneficial effects of polyphenols have been attributed to their antioxidant 
activity [208]. Additionally, polyphenols affect numerous cellular targets that can modu-
late autophagy, which interferes with the symptoms and putative causes of cancers [208]. 
Today, it is widely accepted that dietary flavonoids, including the commonly occurring 
flavonols quercetin and kaempferol, the flavones apigenin and luteolin, green tea cate-
chins, and the isoflavone genistein, have strong anticancer potentials, thus exerting anti-
proliferative, cytotoxic, proapoptotic, anti-inflammatory, antiangiogenic, antimetastatic, 
and antiinvasive activities. The strong potential of these compounds in the fight against 
cancer has been proven in numerous experimental studies, in both in vitro cell cultures as 
well as in animal (rodent) models [208–210]. 
4.2.1. Quercetin 
Quercetin is a well-known antioxidant flavonoid that has antitumor effects [109]. 
Quercetin induces autophagy in different cancer cells through the modulation of the AKT-
mTOR signal pathway [110]. Quercetin triggers autophagy by AMPK activation and the 
accumulation of HIF-1α, which represses mTOR signaling and induces the expression of 
Bcl-2/adenovirus E1B 19 kDa protein-interacting protein 3/ligand (BNIP3/BNIP3L) to dis-
rupt the Beclin1/Bcl-2 (Bcl-xL) complex [110]. Poly(DL-lactide-co-glycolide) quercetin na-
noparticles stimulate autophagy and cell death through the suppression of the 
AKT/mTOR signaling pathway in human neuroglioma cells [110]. Quercetin induces ER 
stress, activates protective autophagy and apoptosis, and simultaneously stimulates sig-
nal transduction and the activation of the transcription axis 3 (p-STAT3)/Bcl-2 in ovarian 
cancer. As a chemopreventive agent, quercetin plays an important role in modulating 
chemotherapeutic drug sensitivity [110]. Quercetin also regulates apoptosis and autoph-
agy-related pathways and facilitates gemcitabine (an analog of deoxycytidine for DNA 
synthesis inhibition) chemosensitivity through the receptor involved in advanced gly-
cation end products (RAGE)/PI3K/AKT/mTOR axis in human pancreatic cancer cells. 
Quercetin also suppresses multidrug resistance protein 1 (MDR1) expression, blocks drug 
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efflux via P-glycoprotein (P-gp) transport proteins, and increases the activity of anti-can-
cer drugs in uterine sarcoma MES-SA cells [110]. Quercetin-induced initial autophagy in 
gastric cancer protects cancer cells from late apoptosis [211]. Rutin, also called rutoside, 
quercetin-3-O-rutinoside, and sophorin isolated from Toona sinensis Roem (Meliaceae), 
has clinically relevant functions as an anti-inflammatory and antioxidant agent [212]. Sim-
ilar to quercetin, luteoloside, isolated from the medicinal plant Gentiana macrophylla, has 
oncosuppressive effects in humans [213]. 
4.2.2. Magnolol 
Magnolol, a plant that is widely used in traditional Japanese and Chinese medicines, 
is isolated from the root of magnolia officinalis. It is well known that magnolol has anti-
inflammatory, anti-diabetic, anti-microbial, anti-neurodegenerative and anti-depressant 
properties. Recently, in vivo and in vitro studies have shown that the treatment of neuro-
blastoma cancer cells with magnolol can induce autophagy/mitophagy and apoptosis in 
treated cells. Importantly, blocking autophagy/mitophagy significantly enhances the anti-
cancer effectiveness of magnolol, suggesting that targeting autophagy/mitophagy can be 
a promising strategy to overcome chemoresistance and to improve cancer therapy [214]. 
4.2.3. Kaempferol 
Kaempferol, a polyphenol flavonoid, is found in different fruits (e.g., grapes) and 
vegetables (e.g., tomatoes). Kaempferol modulates autophagy in noncancerous cells in or-
der to protect cells against malfunction, and it induces cell death by enhancing autophagy 
via the elevation of the p-AMP-activated kinase protein, LC3-II, and Beclin1 in gastric 
cancer cells [111]. 
4.2.4. Apigenin 
Apigenin, a bioflavonoid, is widely present in fruits and vegetables, such as parsley, 
orange, tea, chamomile and seasonings. Apigenin has been shown to possess significant 
anti-inflammatory, antioxidant and oncosuppressive properties. In cancer cells, apigenin 
inhibits growth and proliferation through its preventive effects via the modulation of 
apoptosis and autophagy [112]. The mechanism underlying the anti-tumor effects of apig-
enin in hepatocellular carcinoma HepG2 cells is related to the induction of apoptosis and 
autophagy through the inhibition of the PI3K/AKT/mTOR pathway [113]. However, apig-
enin inhibits autophagy flux in the primary human epidermal keratinocytes (HEKs) and 
the cutaneous squamous cell carcinoma cell line COLO-16. Moreover, apigenin can en-
hance the effect of chemotherapeutic agents and reduce chemoresistance by inhibiting 
drug efflux [112]. Gao et al. [215] investigated the possibility of a chemo-sensitization ef-
fect of apigenin in a Dox-resistant HCC cell line (BEL-7402/ADM). Apigenin treatment 
enhances Dox sensitivity, induces microRNA-520b (miR-520b) expression and inhibits 
ATG7-dependent autophagy in these cells. ATG 7 acts as a potential target of miR-520b 
[215]. Moreover, combined with N-(4-hydroxyphenyl) retinamide, apigenin may sup-
press starvation-induced autophagy and promote apoptosis in human malignant neuro-
blastoma cells [216]. There is also evidence that suggests that apigenin can induce au-
tophagic cell death in human papillary thyroid carcinoma cells [217]. Vitexin (apigenin-8-
C-glucoside, c-glycosylated flavone) is found in various medicinal plants [218]. The bio-
chemical properties of vitexin, such as its anticancer and antioxidant effects, are well-doc-
umented [112]. Vitexin has been reported to inhibit autophagy in a multi-drug-resistant 
(MDR) line of human colon cancer cells (HCT-116DR). Mechanistically, vitexin could re-
duce the level of autophagy in cancer cells (via the suppression of ATG 5 and Beclin1 
expression levels) and simultaneously increase the apoptotic response through the en-
hancement of the cleavage of caspase-3 and -9 [219]. 
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4.2.5. Coffee and Tea: (−)-epigallocatechin-3-gallate (EGCG), Catechin and Epicatechin 
Coffee and tea are the most consumed beverages worldwide, and have an impressive 
impact on the economies of the countries that produce them. Coffee is prepared from the 
seeds of coffee plants, genus Coffea, which include different species. Tea made from the 
leaves of the plant Camellia sinensis is a popular beverage [220]. An elegant study showed 
that caffeine, the main constituent of coffee beans and tea leaves, is a potent stimulator of 
hepatic autophagic flux; caffeine-induced autophagy involves the down-regulation of 
mTOR signaling and alterations in hepatic amino acids and sphingolipid levels. Caffeine 
also promotes AMPK-dependent autophagy through calcium-mediated pathways in skel-
etal muscle cells [221]. It can be found in quantities of up to 70–350 mg per cup of coffee 
and has been linked to numerous health benefits, such as a reduced risk of some forms of 
cancers, including breast cancer [222]. However, coffee consumption has been associated 
with a risk of the development of various forms of cancers, including CRC [223] and blad-
der cancer [224]. Via the inhibition of enzymatic activity of mTORC1, Pietrocola el al. [225] 
has shown that consumption of both natural and decaffeinated brands of coffee by mice 
increases autophagic flux (1-4 h after intake) in the liver, muscles and hearts of the treated 
animals. However, they concluded that caffeine is not only responsible for increased au-
tophagy, but also polyphenols, such as chlorogenic acid (CGA), EGCG, (−)-epigallocate-
chin (EGC), (−)-epicatechin-3-gallate (ECG), catechin and (−)-epicatechin within coffee, 
and tea may have an even stronger effect on autophagy activation and the reduction in 
protein acetylation. CGAs can activate AMPK-dependent autophagy pathways. These 
products show the effect of ameliorating a variety of human diseases, such as cancers 
[114]. The cosmetic industry has shown a growing interest in these polyphenols, since 
they are able to extend longevity significantly under several stress conditions by reducing 
skin aging and age-related diseases [207]. EGCG upregulates AMPK activity in a dose-
dependent manner, while the mTOR pathway is inhibited in hepatoma cells [115]. An 
increasing amount of evidence has shown that the dietary intake of proanthocyanidins 
plays an essential role in the chemoprevention or chemotherapy of tumors [226]. In vitro 
and in vivo toxicity experiments have demonstrated that proanthocyanidins have anti-
cancer effects on various human cancers, such as CRC, pancreatic cancer, HCC, non-small 
cell lung cancer (NSCLC), squamous cell carcinoma (SCC), as well as head and neck squa-
mous cancer. Grape seed proanthocyanidins, formed by the polymerization of catechins 
and/or epicatechins, induce autophagy by inducing the phosphorylation of the mitogen-
activated protein kinase (MAPK) pathway and by reducing the expression of survivin, 
which is a member of the inhibitor of apoptosis (IAP) gene family in HepG2 cells [227]. 
4.2.6. Genistein 
Genistein, a natural isoflavone polyphenol, has been reported to exhibit multiple ben-
eficial effects on human health, including anticancer properties that target multiple cancer 
cells, such as ovarian cancer and human breast MCF-7 cells [116] through several mecha-
nisms, which include the induction of autophagic cell death [117]. Several studies found 
that genistein can potentiate the antitumor effects of chemotherapeutic agents (e.g., 5-FU, 
gemcitabine, cisplatin and oxaliplatin) by modulating the autophagic-apoptotic pathway. 
For instance, the combination of 5-FU and genistein can induce autophagic cell death in 
cancer cells by significantly altering the expression of two important molecules, Bcl-2 and 
Beclin1, which regulate autophagy [117]. The oncosuppressive effect of genistein is asso-
ciated with the inhibition of PI3K-AKT signaling activation [118]. Ali et al. [228] also re-
ported that genistein inhibits nuclear receptor co-repressor (N-CoR) misfolding, which is 
an important component in the activation of the oncogenic survival pathway in NSCLC, 
and was found to be associated with heat shock cognate 70 kDa protein (HSC70), which 
is a molecular chaperone in autophagy. Surprisingly, genistein induces the overexpres-
sion of TFEB, which is a master regulator of lysosomal biogenesis and an enhancer of au-
tophagy protein expression [229]. Moreover, genistein-mediated suppression of mTOR 
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increases dephosphorylation and the subsequent nuclear translocation of TFEB, which is 
associated with a significant increase in lysosomal content and activity in treated cancer 
and non-cancerous cells. Thus, genistein appears to be a potentially beneficial agent in the 
treatment of lysosomal storage diseases and cancers [230,231]. 
4.2.7. Curcumin Derivatives 
Curcumin has been used as a food colorant in dietary supplements and herbal med-
icines in Asian populations [119]. Curcumin has numerous pharmacological activities, in-
cluding antioxidant and anticancer activities [112,120]. Curcumin has been reported to 
induce autophagy in chronic myeloid leukemia, malignant glioma, esophageal cancer, co-
lon cancer, uterine leiomyosarcoma, ovarian cancer and lung adenocarcinoma via mech-
anisms related to the reduction in cell viability, proliferation, migration and invasion 
[119]. Curcumin also induces autophagy-associated apoptosis in mesothelioma and 
chronic myelogenous leukemia cells by modulating PI3K/AKT/mTOR and the nuclear fac-
tor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling pathways [112]. Cur-
cumin inhibits the growth of malignant gliomas, lung adenocarcinoma and melanoma 
cells in vitro and in vivo by downregulating the PI3K/AKT/mTOR signaling pathway and 
activating the AMPK pathway, and finally by promoting autophagy [112]. In addition, 
curcumin induces apoptosis in human malignant mesothelioma, which is an aggressive 
malignancy and is inherently chemo-resistant [112,121]. Curcumin-induced cell death is 
highly correlated with the enhancement of apoptosis or autophagy, mitochondrial mem-
brane potential (MMP) and the activation of caspase-3. In addition, curcumin can reduce 
the expression of Bcl-2 proteins in K562 cells [122,123]. Curcumin has been shown to acti-
vate mitochondrial-mediated apoptosis and autophagy in adriamycin-induced human 
hepatoma G2 (HepG2) [123], due to the reduced proportion of Bcl-2/Bax protein and 
caspase-3 activation. Moreover, curcumin treatment can result in the mitochondrial fis-
sion of HepG2 cells, the reduction in MMP and autophagy activation [123]. It has been 
proposed that curcumin reverses cisplatin chemoresistance via the regulation of oxidative 
stress and autophagy flux in the MDR cell line A549/cDDP [112]. Curcumin also sensitizes 
MDR breast cancer cells to cisplatin treatnment and activates autophagy by suppressing 
the PI3K/AKT/mTOR pathway [112]. Interestingly, curcumin also regulates prosurvival 
autophagy in HCT116 cells that are mediated by the overexpression and nuclear translo-
cation of TFEB and the inhibition of mTOR [121,232]. The monocarbonyl analog of curcu-
min, B19 or curcumin bis-dehydroxy, induces autophagy and apoptosis via the ER-stress 
route in ovarian and colon cancer cells [118]. The curcumin analogue, hydrazinobenzo-
ylcurcumin, can also induce autophagic cell death in human non-small lung epithelial 
carcinoma (A549) cells [121]. Tetrahydrocurcumin, a major metabolite of curcumin, sig-
nificantly reduces the activity of the PI3K/AKT/mTOR and MAPK signaling pathways 
and induces autophagic cell death in human leukemia HL-60 cells [233,234]. Another cur-
cumin analogue, the 3,5-bis (2-hydroxybenzylidine) tetrahydro-4H-pyran-4-1 glutathione 
conjugate (EF25-[GSH]2), inhibits the growth of hepatocellular carcinoma in vitro and in 
vivo by modulating the autophagic pathway and enhancing apoptosis [235]. Besides acti-
vating autophagy, curcumin also exhibits time- or concentration-dependent inhibition of 
cell proliferation, autophagy and apoptosis in K562 cells, SKN and SK-UT-1 uterine leio-
myosarcoma cells [236]. Curcumin therapy has been reported to mitigate autophagy and 
to reverse drug-resistance through the potent activation of Keap1 transcription, which is 
crucial for the erythroid 2 like 2 (Nrf2) signaling pathway [112,237]. 
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4.2.8. Resveratrol 
Resveratrol has the potential to slow down the progression of many age-related dis-
eases (ARDs), including different types of cancer. Resveratrol has potentially beneficial 
effects, including improving mitochondrial quality control and glucose tolerance through 
AMPK activation [118]. Several studies have suggested the growth inhibitory efficacy of 
resveratrol in several types of cancer cell, such as HCC, breast cancer, gastric cancer and 
leukemia [124]. Interestingly, resveratrol significantly inhibits breast cancer stem cell pro-
liferation by inducing autophagy through the suppression of the Wnt/β-catenin signaling 
pathway. Resveratrol treatment in cancer cells results in autophagic cell death via multi-
ple pathways, including JNK-mediated p62 expression, AMPK activation and the Beclin1-
independent pathway [125]. Resveratrol has been reported to reduce AKT phosphoryla-
tion and mTOR signaling by p70S6K, which is a direct mTOR substrate. Resveratrol treat-
ment decreases ER Ca2+ storage and store-operated calcium entry (SOCE), which induces 
ER stress, thereby activating AMPK and inhibiting the AKT/mTOR pathway [126]. More-
over, some studies have also suggested that resveratrol may potentially be useful in cancer 
chemotherapy for HCC and leukemia, when used in combination with other drugs, 
mainly due to its effect on apoptosis [126]. Rapamycin, in combination with resveratrol, 
significantly inhibits the growth of estrogen receptor-positive and estrogen receptor-neg-
ative breast cancer cells by preventing the activation of the AKT pathway, autophagy, and 
stimulating apoptosis [121]. In another study, resveratrol, in combination with the carfil-
zomib proteasome inhibitor (at low concentrations), synergistically increases apoptosis in 
myeloma cells through the simultaneous induction of autophagy [238]. This compound 
can also increase the susceptibility of melanoma, prostate and NSCLC cancers to chemo-
therapy [112]. In another study, resveratrol was reported to attenuate autophagy in ciga-
rette smoke-induced cytotoxic stress responses in lung cells via the activation of SIRT1, 
which is a potent inducer of autophagy [121]. Pterostilbene (trans-3,5-dimethoxy-4-hy-
droxystilbene), a resveratrol analogue, triggers autophagy-induced apoptosis in cisplatin-
resistant human oral cancer cells via the triggering of SIRT1 [239]. 
4.2.9. Propolis Extract: Chrysin 
Propolis is a complex resinous mixture produced by honeybees and has multiple 
pharmacological properties, including anticancer activity. Brazilian green propolis ex-
tract, which contains the active ingredients cinnamic acid derivative artepillin C, is an 
attractive agent for cancer treatments [127]. In addition, the ethanol extracts of Chinese 
and Brazilian green propolis have been reported to induce autophagy in prostate cancer 
CWR22Rv1 cells via the upregulation of LC3-II [127]. The apoptosis induced by artepillin 
C is exacerbated by cotreatment with autophagy inhibitors, such as CQ [127]. A number 
of studies have confirmed the biological properties of chrysin, including its anti-inflam-
matory and anti-tumor activity [240]. Chrysin is an effective component in sensitizing hu-
man glioblastoma cells (GBM8901) to temozolomide (TMZ). It inhibits TMZ-induced au-
tophagy by reducing the expression levels of LC3-II, ATG7 and Beclin1, and by suppress-
ing the expression of O6-methylguanine-methyltransferase (MGMT) DNA, which may be 
involved in chemoresistance to TMZ [112]. 
4.2.10. Fisetin 
Fisetin, a flavonoid polyphenol, is known to exhibit multiple pharmacological activ-
ities, including anti-inflammatory and anticancer activities in various cell types, such as 
prostate, colon, breast, and leiomyoma cells [128]. Fisetin induces autophagy and apopto-
sis in various cancer cells, such as pancreatic cancers and human melanoma, via ER stress-
and mitochondrial stress-dependent pathways [128]. Treatment of prostate cancer cells 
with fisetin suppresses mTOR activity and downregulates the subunits Raptor, Rictor, 
PRAS40 and GβL, in addition to activating the mTOR repressor tuberous sclerosis com-
plex 2 (TSC2). Fisetin has been shown to be a dual inhibitor of PI3K/AKT and mTOR in 
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prostate cancer cells and in human NSCLC cells, as well as an inducer of autophagy in 
pancreatic cancer cells via ER stress- and mitochondrial stress-dependent pathways 
[129,130]. Fisetin has been reported to induce autophagic-programmed cell death rather 
than cytoprotective autophagy in human NSCLC, liver cancer, prostate cancer, laryngeal 
cancer, and uterine leiomyomas, all through apoptosis signaling pathways [129]. Fisetin’s 
effects on autophagy are cell-type-dependent, since this compound inhibits autophagy in 
HepG2 cells via the PI3K/AKT/mTOR and AMPK pathways [241]. 
4.2.11. Rottlerin 
Rottlerin, a traditional Indian subcontinent medicine, displays antioxidant properties 
and anticancer potential against different cancer cells, e.g., breast cancer, with various 
mechanisms, including the induction of autophagy and apoptosis [118]. Singh et al. [137] 
reported that 2 µM rottlerin (24 h treatment) activates autophagy in pancreatic cancer stem 
cells by inhibiting mTOR signaling. In prostate cancer stem cells, it represses mTOR, 
which is accompanied by an increase in the expression of ATG proteins, including ATG5, 
ATG7, ATG12 and Beclin1 [138,139]. In addition, it is a protein kinase C δ (PKC-δ)-selec-
tive inhibitor, which in turn leads to the suppression of NF-κB signaling and the conse-
quent activation of autophagy in breast, pancreatic and colon cancer cells. [139]. Rottlerin 
inhibits NF-κB and activates AMPK in breast and colon cancerous cells, resulting in a sig-
nificant reduction in cellular ATP levels and autophagy induction. Rottlerin-induced au-
tophagy leads to apoptotic cell death by multiple signaling pathways, such as 
PKCδ/transglutaminase 2 (TG2)-dependent and -independent pathways in pancreatic 
cancer cells, PKCδ-independent mechanism in HT1080 human fibrosarcoma cells, and in-
hibition of PI3K/AKT/mTORC1 pathways in prostate cancer stem cells (CSCs) [138], 
breast CSCs [242] and human pancreatic CSCs [137]. 
In addition, a variety of polyphenolic natural compounds or nutraceuticals isolated 
from fruits, vegetables, spices, nuts, legumes, herbs, etc., also regulate autophagy signal-
ing pathways and exhibit potent anticancer activities. For example, cucurbitacin B en-
hances the anticancer effects of clinical chemotherapeutic drugs, including cisplatin, gem-
citabine, methotrexate, docetaxel, and gemcitabine. It induces autophagy and DNA dam-
age, as evidenced by the increasing ROS formation and autophagic protein expression in 
MCF-7 breast cancer cells [131,132]. Wogonin exerts inhibitory growth effects on the SW48 
CRC cells by inducing autophagic and apoptotic cell death via modulating the PI3K/AKT 
signaling pathways. Wogonin upregulates autophagic proteins such as LC3II and Beclin1, 
in addition to apoptotic proteins, such as caspase 3, 8 and 9 and Bax [125,133,134]. Morusin 
has been highlighted for its versatile potential against human pathologies, including can-
cer and immune dysfunctions. Morusin treatment leads to mTOR1 inhibition and the sub-
sequent activation of AMPK, resulting in ULK1-mediated autophagy activation [135,136]. 
Naringin inhibits human gastric carcinoma, via the induction of autophagy, by activating 
Beclin1 and LC3-II via the activation of MAPKs pathways [243]. 6-C-(E-phenylethenyl) 
naringenin (6-CEPN) has been shown to suppress colon cancer cell proliferation via the 
induction of necrotic cell death and autophagy by the inhibition of c-Raf/MAPK 
(MEK)/ERK and PI3K/AKT/mTOR signaling pathways [244]. 
4.3. Terpenoids 
Paclitaxel and its semisynthetic analogue docetaxel have been widely prescribed 
antineoplastic agents (approved by the FDA in 1992) over the past several decades for a 
broad range of malignancies, such as ovarian cancer, breast cancer, and NSCLC, either as 
a monotherapy or in combination with cisplatin. The anticancer activity of this drug is 
attributed to its unique mechanism of action, i.e., causing mitotic arrest in cancer cells, 
which leads to apoptosis through the inhibition of microtubule depolymerization [60]. 
However, resistance to paclitaxel has become a major limitation of clinical success [140]. 
While the molecule or key mechanism associated with paclitaxel resistance in cancers re-
mains uncertain, paclitaxel’s regulation of autophagy is one reason. It has been reported 
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that paclitaxel promotes autophagy in ovarian cancer, cervical cancer SiHa cells, lung can-
cer cells, gastric cancer BGC823 cells and bladder urothelial carcinoma (BUC) cells [60]. 
Paclitaxel treatment has also been found to induce autophagy in A549 cells, U87 glioma 
cells, human PC-3 prostate cancer and colon HT-29 cancer cells via the increasing expres-
sion levels of LC3-II, ATG5 and Beclin1 in a dose-dependent manner. Additionally, 
paclitaxel-induced autophagy has been reported to play a critical role in mediating 
caspase independent cell death. Paclitaxel also inhibits autophagy in breast cancer cells 
and cervical cancer cells [60,141], suggesting that paclitaxel has different effects on au-
tophagy in various cancer cells. As paclitaxel may generate unacceptable levels of toxicity 
in normal cells in clinical settings, more experiments need to be focused on how to en-
hance its effectiveness as well as to reduce its toxicity. 
4.3.1. γ-Tocotrienol 
The use of tocotrienols, such as α-tocotrienol, β-tocotrienol, γ-tocotrienol and δ-to-
cotrienol, as dietary supplements in Asian populations is considerably higher than in de-
veloped countries. Most obviously, tocotrienols, members of the vitamin E superfamily, 
are characterized by their antioxidant, anti-inflammatory and anticancer activity [121]. Ti-
wari et al. [142] found that γ-tocotrienol treatment in breast cancer cells could induce ER 
stress and concurrent autophagy-mediated cell death. Oridonin (7,20-epoxy-ent-kau-
ranes), a diterpenoid isolated from the medicinal herb Rabdosia rubescens, has been 
shown to display potent anticancer activity against a wide ranges of cancer cell types, such 
as breast cancer cells, melanoma and cervical carcinoma cells by inducing autophagy-me-
diated apoptosis [142]. In combination with oridonin, γ-tocotrienol has been shown to 
synergistically induce autophagic and apoptotic effects in mouse breast cancer cells [142]. 
This combination significantly enhanced the expression of autophagy markers, including 
LC3B-II, Beclin1, ATG3, ATG7, ATG5-ATG12 and cathepsin D [142]. γ-tocotrienol treat-
ment promotes apoptosis and autophagy in human prostate cancer PC-3 and LNCaP cells 
[245]. Tocomin, which is a mixture of naturally occurring tocotrienols (T3s), inhibits pro-
liferation and induces apoptosis in breast cancer cells [246]. 
4.3.2. Ursolic Acid 
Ursolic acid exhibits antitumoral activity by inhibiting proliferation, suppressing 
DNA replication, inducing the release of Ca2+, and activating caspases in several cancers, 
including breast carcinoma, melanoma, leukemia, hepatoma and prostate cancer [121]. In 
vivo, ursolic acid inhibits the growth of HCT15 cells by modulating autophagy involving 
the JNK pathway [121]. The pro-autophagic effects of ursolic acid in the suppression of 
TC-1 cervical cancer cells and NSCLC cells have been reported to be mediated by LC3-II 
and ATG5, depending on the concentration. In addition, ursolic acid triggers autophagy 
in MCF7 breast cancer cells through ER stress [121,144]. In another study, ursolic acid 
induced autophagy and apoptosis in glioblastoma U87MG cells by three different mech-
anisms, including phosphorylated extracellular signal-regulated kinase (PERK)/eukary-
otic initiation factor 2α (eIF2α)/C/EBP homologous protein (CHOP), calmodulin-depend-
ent kinase protein kinase (CaMMK)/AMPK/mTOR, and inositol-requiring enzyme 1α 
(IRE1α)/JNK signaling [121]. Ursolic acid-induced autophagy in PC3 prostate cancer cells 
is mediated by the Beclin1 and AKT/mTOR pathways [121,144]. 
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4.3.3. β-Elemene 
β-elemene inhibits the activity of the PI3K/AKT/mTOR/p70S6K1 pathway, thus trig-
gering autophagy and apoptosis in human NSCLC A549 cells and human renal-cell carci-
noma 786-0 cells [121]. In the treated cells, induction of autophagy is protective, since the 
inhibition of autophagy with CQ significantly enhances the antitumor effect of β-elemene 
[121]. β-elemene has been shown to have the potential to reverse chemotherapeutic drug 
resistance. For example, β-elemene increases the sensitivity of 5-fluorouracil in p53 wild-
type CRC cells [145] and reverses the resistance to gefitinib in NSCLC [146]. 
4.3.4. (−)-Guaiol 
(−)-Guaiol is well known for its antibacterial activity [147]. (−)-Guaiol inhibits the pro-
liferation of NSCLC cells by inducing autophagy via specifically targeting mTOR phos-
phorylation at serine 2481 signaling pathways [147]. 
4.3.5. Sesquiterpene Lactones: F1012-2 
Sesquiterpene lactones (SLs), such as F1012-2, thapsigargin, parthenolide, and iso-
alentolactone, are plant-derived constituents that have a variety of biological activities in 
inhibiting proliferation, migration, invasion and inducing apoptosis in different types of 
cancer cells, such as lung cancer, breast cancer, leukemia, and CRC [148]. F1012-2 isolated 
from a perennial herbaceous plant (Eupatorium lindleyanum DC) inhibits the cell growth 
of triple negative breast cancer (TNBC) (MDA-MB-231 and MDA-MB-468) [148]. The cell 
growth inhibitory mechanisms of F1012-2 in TNBC cells are demonstrated by inducing 
apoptosis in a caspase-dependent manner, as well as the activation of autophagy. Simul-
taneously, F1012-2-induced apoptosis is enhanced by the inhibition of autophagy [148]. 
Similarly, ergolide [247], anthecotulide [248], CLE-10 [249], elephantopinolide A-P [250], 
and bigelovin [251] activate apoptotic and autophagic pathways in malignant melanoma, 
breast cancer (MDA-MB-231), HCC and liver cancer cells, respectively. Calcium ions 
(Ca2+) are an essential factor for the regulation of autophagy, because it has been shown 
that Ca2+ release helps to drive membrane fusion to a particular area from the ER, in the 
vicinity of autophagosomes and lysosomes by binding with IP3R [42]. Thapsigargin (TG) 
causes the transient elevation of cytosolic Ca2+ release from ER stores and the depletion of 
intracellular Ca2+ stores in several cells types due to the potent and specific inhibition of 
intracellular Ca2+ ATPases (sarcoplasmic-/endoplasmic reticulum sarco/ER Ca2+ ATPase, 
SERCA) [252]. TG therapy also leads to necrotic cell death, which results from excessive 
damage to the mitochondrial pool and activation of autophagy independent mTOR path-
ways [252]. The role of TG in autophagy is debated, with earlier reports claiming both 
inductive and inhibiting effects [148]. TG inhibits autophagy by specifically blocking au-
tophagosome–lysosome fusion, as well as autophagic flux by interfering with Rab 
GTPases and Rab7 function [148]. 
4.4. Saponin Compounds 
4.4.1. Tubeimoside-1 
Tubeimoside-1 (TBMS1) has been proven to have potent anticancer activities in hu-
man prostate, lung, liver, cervical, and gastric cancer cells [149]. TBMS1 is identified as a 
potent activator of autophagy in human breast and liver cancer cells via LC3-II accumu-
lation [150] and AMPK activation [151]. Inhibition of cytoprotective autophagy can en-
hance the cytocidal effect of TBMS1 in breast cancer cells by promoting apoptotic cell 
death [150]. TBMS1 inhibits cell proliferation in melanoma cells in vitro and tumorigene-
city in vivo. Interestingly, TBMS1 inhibits cell proliferation by the activation of the 
MEK1/2-ERK1/2 pathway on the one hand, and it triggers cytoprotective autophagy in 
melanoma cells on the other hand. The strength of the two opposing forces determines 
the fate of the cells. TBMS1 also interacts with protein-tyrosine phosphatase 1B (PTP1B), 
which further hyperactivates MEK1/2-ERK1/2 cascades, leading to the inhibition of cell 
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proliferation and the partial distortion of prosurvival autophagy [253]. Another interest-
ing report suggests that TBMS1 exerts anticancer effects in lung cancer cells via blocking 
of the late-stage of autophagy flux via the impairment of lysosomal acidification through 
v-ATPase inhibition and the induction of apoptosis by lysosomal-dependent pathways. 
TBMS1 promotes mitochondrial fission and the dynamin-related protein (DRP1), which 
is a small GTPase-mediated fragmentation, and thereby leads to ROS accumulation. Im-
pairment of lysosomal acidification blocks the removal of dysfunctional mitochondria and 
results in ROS accumulation; this causes further damage to the lysosomal membrane and 
leads to cathepsin B leakage from lysosomes. This leakage upregulates the Bax-mediated 
MOM potential (MOMP), and subsequently, cytosolic cytochrome c-mediated caspase-
dependent apoptosis [254]. 
4.4.2. Paris Polyphylla 
The Paris polyphylla extract has been reported to inhibit cell growth, EMT and inva-
sion in breast cancer, ovarian carcinoma and lung cancer cells [152]. Moreover, pen-
nogenin 3-O-beta-chacotrioside and polyphyllin VI are active components of the ethanolic 
extract from P. polyphylla (EEPP), inducing cell death in DLD-1 human CRC via the up-
regulation of autophagy markers LC3-II and Beclin1. In addition, EEPP therapy, in com-
bination with Dox, improves cytotoxicity in these malignant cells [152]. Diosgenin-en-
riched P. polyphylla rhizome extract (DPPE) shows cytotoxicity and anti-cancer activities 
in breast cancer cells [255]. 
4.4.3. Ophiopogonin B 
Ophiopogonin B has been verified to inhibit cell proliferation in numerous NSCLC 
cells. Ophiopogonin B induces autophagy in H157 and H460 cells and adenocarcinoma 
A549 by upregulating the conversion of LC3-I to LC3-II and increasing the expression of 
ATG3 and ATG5-ATG12 in treated cells [153]. 
4.4.4. Betulinic Acid 
Betulinic acid (BA) exhibits a variety of biological activities, including anticancer ef-
fects. The anticancer activity has been linked to its ability to directly trigger autophagy-
mediated apoptosis via the mitochondrial pathway, such as MMP [154]. BA inhibits cell 
proliferation and induces apoptosis in CRC cells, HepG2 and SMMC-7721 HCC [155]. BA 
treatment induces autophagy via the inhibition of the AKT/mTOR signaling pathway. 
Blockage of autophagy enhances BA-induced proliferation inhibition and apoptosis in 
CRC cells [156]. BA inhibits breast cancer metastases by targeting glucose-regulated pro-
tein 78 (GRP78), a major chaperone in ER that is frequently strongly expressed in most 
solid tumors. This GRP78 chaperone contributes to the acquisition of metastatic pheno-
types, including apoptosis resistance and drug resistance [256]. The reduced congener of 
BA, botulin, also has several pharmacologic effects, including anti-cancer effects. Betulin 
exhibits inhibitory effects on colorectal metastasis by inducing cell-cycle arrest and au-
tophagy in metastatic CRC cells via AMPK and PI3K/AKT/mTOR signaling pathways. In 
addition, betulin induces caspase-dependent apoptosis via decreasing the phosphoryla-
tion of the MAPK signaling pathway in metastatic CRC cells [257]. 
4.5. Alkaloids 
4.5.1. Camptothecin 
Camptothecin (CPT), a potent topoisomerase I inhibitor, displays oncosuppressive 
activities against leukemia, human colon cancer and a variety of solid tumor systems 
[157]. Interestingly, the combination of miR-15a and miR-16, which are two potent induc-
ers of autophagy, enhances the chemotherapeutic efficacy of CPT against cancer cells 
[157]. CPT enhances c-Myc-mediated ER stress and ROS generation, leading to autophagy 
activation via the induction of Ca2-mediated AMPK and the JNK/activator protein 1 (AP-
Int. J. Mol. Sci. 2021, 22, 9807 43 of 63 
 
1) pathway [158]. CPT also generates ROS to modulate the AMPK/mTOR/ULK1 axis in 
order to finally promote protective autophagy in esophageal cancer [159]. The combina-
tion of CPT and pulsatilla saponin D, a powerful autophagy inhibitor, has a synergistic 
anti-breast cancer effect by interrupting autophagic-lysosomal function and promoting 
ubiquitous p62 mediated protein aggregation [258]. CPT derivatives, such as belotecan 
and methylenebis, also induce autophagy, but with different mechanisms. Belotecan in-
duces autophagy by decreasing the level of p62, whereas methylenedes do not affect the 
level of p62, but upregulate the level of LC3-II. Interestingly, methylenebis and belotecan 
enhance the synergic antitumoral efficacy by inducing the apoptosis of tumor cells [259]. 
4.5.2. Berberine 
Berberine (BBR) has diverse pharmacological properties, including cancer modula-
tion [160,161]. BBR induces autophagic cell death and apoptosis in human gastric cancer, 
glioblastoma multiforme (GBM), breast cancer, and hepatoma cells by the activation of 
Beclin1, as well as the inhibition of the mTOR signaling pathway [160,161]. BBR-associ-
ated photodynamic therapy induces autophagy and apoptosis in renal carcinoma cells 
[162]. In addition, BBR has been shown to induce autophagic cell death by increasing the 
binding capacity of GRP78 levels in cancer cells [160,161]. BBR sensitizes human HCC to 
ionizing radiation by blocking autophagy and cell-cycle arrest, which results in senes-
cence [260]. 
4.5.3. Tetrandrine 
Tetrandrine (TET) possesses multiple pharmacological properties against a wide va-
riety of cancers [163]. The antitumor effects of TET are associated with the induction of 
apoptosis and autophagy, the reversal of MDR, and the enhancement of radiation sensiti-
zation [163,164]. TET has been proven to be a potent broad-spectrum autophagy agonist 
with effects on a variety of cell lines, including triple-negative breast cancer cells, human 
HCC, nasopharyngeal carcinoma by inhibiting PI3K/AKT/mTOR signaling [164,165]. TET 
inhibits human PML-RARα-positive acute promyelocytic leukemia (APL) cell prolifera-
tion and induces autophagy by activating ROS generation and Notch1 signaling [261]. 
TET induces autophagy and apoptosis in a dose-dependent manner in pituitary adenoma 
(PA) cells. TET induces autophagy in these cells by down-regulating the MAPK/STAT3 
signal at low concentrations (1.25 µM). However, at a higher dose (5.0 µM) of TET, pitui-
tary adenoma (PA) cells partially die from caspase-dependent apoptosis [262]. Unlike an 
autophagy enhancer, Qiu et al. presented TET as a powerful lysosomal inhibitor, blocking 
the autophagic flux at the lysosomal degradation step in tumor cells [263]. TET increases 
the sensitivity of different cancer cells to gefitinib [264], cisplatin [265] and tamoxifen 
[266]. 
4.5.4. Protopine 
Protopine exhibits a number of pharmacological properties, including anticancer ac-
tivities. Protopine suppresses the cell proliferation of colon cancer, inhibits cell adhesion 
in breast cancer and induces apoptotic cell death in prostate cancer [166]. Protopine is 
capable of activating p53-mediated transcriptional activity and promotes the stabilization 
of the p53 protein. Protopine induces autophagy by enhancing LC3-II turnover, along 
with reducing the levels of p62 in human colon cancer cells [166]. 
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4.5.5. Neferine 
Neferine possesses antitumor activity via the suppression of cell proliferation and 
the inhibition of cell growth in different human cancers [167]. Neferine can induce au-
tophagy in various cancer cells, such as human ovarian cancer via the inactivation of 
mTOR and the activation of p38 MAPK/JNK signaling pathways [168]. Neferine induces 
autophagic cell death in a panel of cancer cells, including apoptosis-defective and -re-
sistant cancer cells or isogenic cancer cells, via Ca2+ mobilization through the activation of 
ryanodine receptor and ULK1/PERK and AMPK/mTOR signaling cascades [169]. Ne-
ferine also enhances the tumor necrosis factor (TNF)-related apoptosis-inducing ligand 
(TRAIL)-mediated autophagic cell death in human prostate cancer cells via the JNK path-
way [267]. Furthermore, neferine provokes autophagy and apoptosis in human neuroblas-
toma cells by reducing the levels of focal adhesion kinase (FAK) and 70 kDa ribosomal S6 
kinase 1 (S6K1) [268]. Neferine induces ROS-dependent mitochondrial mediated apopto-
sis by increasing the expression of proapoptotic proteins Bax, cytochrome c, cleaved 
caspase-3 and caspase-9. It also activates autophagy via increasing Beclin1, ATG4, ATG5 
and ATG12, LC3-II expression levels in cervical cancer cells [269]. Additionally, neferine 
enhances cisplatin-induced autophagic cell death in human lung adenocarcinoma via 
downregulation of the PI3K/AKT/mTOR signaling pathway [270]. Further evidence sug-
gests that the neferine anti-angiogenesis mechanism in high-grade serious ovarian carci-
noma occurs by inducing autophagy through the inhibition of the mTOR/p70S6K path-
way and the suppression of the polarization of M2 tumor-associated macrophages [271]. 
4.5.6. Graveoline 
Graveoline triggers autophagic cell death in skin melanomas via the elevation ROS 
generation [170]. 
4.6. Quinonoids 
Quinonoid compounds participate in multiple biological oxidative systems by serv-
ing as prime links in electron transport chains of the metabolic pathways. This redox char-
acteristic accounts for the inherent cytotoxicity of quinonoids. 
4.6.1. Thymoquinone 
Thymoquinone (TQ) has been revealed to exert outstanding pharmacological poten-
tial, including anticancer effects in both in vitro and in vivo models. TQ exhibits a high 
anticancer efficacy against various cancers cells, such as breast, lung, colon, ovary, larynx 
cervical, and prostate cancer, as well as multiple myeloma, myeloblastic leukemia, glio-
blastoma and osteosarcoma [171]. While the impact of TQ has been studied in many types 
of cancer, the molecular mechanisms underlying its action are complex and paradoxical 
due to the multiple targets (e.g., carcinogen metabolizing enzymes, transcription factors, 
etc.) involved in tumorigenesis or development of drug resistance [172]. TQ inhibits the 
metastasis of renal cell cancer cells [173], breast cancer cells [174] and human renal carci-
noma cells [272] by inducing autophagy via the generation of ROS and the activation of 
the AMPK/mTOR signaling pathway. By inducing the chemomodulatory potential, TQ 
synergizes gemcitabine anti-breast cancer activity against human breast adenocarcinoma 
and ductal carcinoma cells via modulating its apoptotic and autophagic activities [174]. A 
combination of TQ with cisplatin diminishes the resistance fraction of cisplatin and im-
proves its anticancer activity against head and neck cancer cells [273]. Similarly, TQ, in 
combination with TMZ, which is currently part of the standard treatment for glioblastoma 
(GBM), potently inhibits the growth of human GBM cell lines by transcriptional impair-
ment of autophagy and the activation of apoptosis [274]. TQ has been shown to induce 
caspase-independent autophagic cell death in colon cancer cells via mitochondrial dys-
function (by induction of MOMP and activation of JNK and p38) [121,275]. 
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4.6.2. Celastrol 
Celastrol is known for its potent anticancer activities. It has been demonstrated that 
celastrol inhibits the proliferation of various cancer cells and the growth of tumors in pre-
clinical mouse models [121]. Celastrol can induce paraptosis, autophagy and apoptosis in 
different cancer cells, including HCC and osteosarcoma cells by modulating multiple 
pathways such as ER stress [121,175–177]. Celastrol has been reported to induce autoph-
agy and apoptosis in different tumor cells, such as glioma and gastric cancer via the 
ROS/JNK and AKT/mTOR signaling pathways [276,277]. Furthermore, co-treatment of 
NSCLC cells with celastrol and erastin, which are ferroptosis inducers, initiates 
ATG5/ATG7-dependent autophagy and PINK1/Parkin-dependent mitophagy via the 
generation of ROS, the disruption of MMP and the promotion of mitochondrial fission 
[278]. Celastrol also stimulates Ca2+-mediated autophagic cell death by inhibiting both 
SERCA and P-gp in MDR tumor cells [279]. In combination with afatinib, celastrol induces 
paraptosis and subsequent cell death in NSCLC via ER stress, ROS accumulation and mi-
tochondrial Ca2+ overload [280]. Celastrol also induces lipophagy via the activation of the 
liver-X receptors α (LXRα)/ATP-binding cassette transporter A1 (ABCA1) pathway in 
clear cell renal carcinoma [281]. Celastrol promotes Nur77 translocation from the nucleus 
to the mitochondria, where it interacts with TNF receptor-associated factor 2 (TRAF2), a 
scaffold protein and E3 ubiquitin ligase that is important in inflammatory signaling [282]. 
In human prostate cancer cells, celastrol induces autophagy by targeting the androgen 
receptor (AR)/miR-101. Celastrol-induced autophagy inversely correlates with AR expres-
sion levels, which in turn suppresses miR-101 expression, and thereby augments prostate 
cancer cell death [283]. Celastrol acts as a sensitizing agent to TRAIL-initiated lung cancer 
cell death via ROS generation and a decrease in MMP [284]. 
4.6.3. Pristimerin 
Pristimerin has been reported to provide a variety of anticancer activities via trigger-
ing autophagy-mediated cell death through ROS production and the activation of the JNK 
signaling pathway [178,179]. 
4.6.4. Plumbagin 
Plumbagin has been shown to exert a wide spectrum of pharmacological effects, in-
cluding anticarcinogenic action against a variety of human cancer cells [180]. Accumulat-
ing evidence shows that the anticancer effects of plumbagin are mainly attributed to the 
induction of autophagy and apoptosis through intracellular ROS generation, activation of 
the AMPK pathway and inhibition of the PI3K/AKT/mTOR pathway [181–183]. 
4.7. Omega-3 Polyunsaturated Fatty Acids (ω-3-PUFA) 
The ω3-PUFAs mainly consist of eicosapentaenoic acid (EPA) and docosahexaenoic 
acid (DHA). The anticancer properties and mechanism of action of ω3-PUFAs have been 
demonstrated in several cancers; however, autophagic and apoptotic cell death are the 
main mechanisms of DHA-induced cytotoxicity in these tumor cells. DHA induces au-
tophagy and apoptosis in human cancer cells harboring wild-type p53 [187] and in pros-
tate cancer cells expressing mutant p53 [188] through p53/AMPK/mTOR signaling [189]. 
ω3-PUFAs, including high-dose DHA, cause apoptotic and autophagic cell death in GBM 
cell lines by upregulating the expression of p62 [285], inducing PARP cleavage and acti-
vating the AMPK/mTOR pathway [286]. Increasing evidence shows that ω3-PUFAs ex-
hibit anti-melanoma activity. Treatment of pulmonary melanoma with DHA-rich algal oil 
induces autophagy by inactivating mTOR and activating the JNK pathway, resulting in 
significant suppression of cell outgrowth. [287]. DHA promotes immunogenic apoptosis 
by inhibiting the STAT3 pathway in human multiple myeloma cells with no toxicity in 
peripheral blood mononuclear cells (PBMCs) and dendritic cells (DCs). It also activates 
autophagy in PBMCs and DCs, which potentially act as immune boosts [288]. There is 
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evidence that EPA and DHA also induce anticancer effects by means of their conversion 
to their corresponding ethanolamine derivatives in breast carcinomas. This is done by 
binding and activating different receptors and distinct signaling pathways [289]. For in-
stance, DHA and EPA-dopamine conjugates, such as DHA-dopamine (DHADA) and 
EPA-dopamine (EPADA), inhibit cell growth and trigger autophagy and apoptosis in 
breast cancer cells via the peroxisome proliferator-activated receptor γ (PPARγ) [290]. Co-
treatment of retinoic acid and ω-3 PUFA activates autophagy in breast cancer cells by ac-
tivating the p38 MAPK signaling pathways [291]. DHA enhances the anticancer drug ox-
aliplatin-induced autophagic cell death via activating Sestrin 2 and increasing ER stress 
in CRC cells [292]. Co-treatment with DHA and vitamin E delta-tocotrienol (Delta-T3) re-
duces lipid droplet biogenesis and potentiates lipophagy in TNBC MDA-MB-231 cells, 
resulting in the mitigation of breast cancer malignancy [293]. 
4.8. Miscellaneous 
4.8.1. Trichostatin A 
Several histone deacetylase inhibitors (HDACIs), such as trichostatin A (TSA), SAHA 
(also known as vorinostat) and depsipeptide, have been widely studied as cancer thera-
peutic agents. TSA-induced apoptosis is associated with multiple mechanisms, with the 
most likely being the modulation of autophagy. The molecular mechanisms underlying 
TSA-mediated autophagy are still not clear, and autophagic cell death remains controver-
sial and most likely context-dependent. TSA is able to induce autophagy in human cancer 
cells through the inhibition of the mTOR pathway and enhancing forkhead box protein1 
(FOXO1)-dependent pathways [184]. Histone deacetylase inhibitors, valproic acid and 
TSA induce apoptosis and autophagy in pancreatic cancer cells by increasing ROS pro-
duction and triggering mitochondrial membrane depolarization, cytochrome c release 
and caspase 3 activation [185]. In cervical cancer cells, TSA (1 µM) induces autophagy by 
significantly suppressing protein arginine methyltransferase 5 (PRMT5) and transient re-
ceptor potential cation channel, subfamily V, member 6 (TRPV6) levels and enhancing 
stanniocalcin 1 (STC1) and JNK levels [186]. TSA suppresses cervical cancer cell prolifer-
ation and induces autophagic cell death through the regulation of the 
PRMT5/STC1/TRPV6/JNK axis. In NSCLC patients, TSA treatment enhances autophagy 
and reverses the chemoresistance of docetaxel or paclitaxel associated with insulin-like 
growth factor (IGF) binding protein-2 (IGF-BP2) expression, which has been shown to 
promote tumorigenesis, metastasis, and cancer stem cell expansion [294]. TSA reduces cell 
viability in cisplatin-resistant human ovarian cancer cells by inhibiting the volume-sensi-
tive organic anion channel (VSOAC) via the induction of taurine transporter (TauT) activ-
ity and inducing autophagic cell death [295]. In combination with the autophagy inhibitor 
CQ, TSA synergistically exerts anti-tumor activity in H-ras transformed breast epithelial 
cells by blocking the mTOR-signaling pathway [296]. Co-treatment with the PI3K/mTOR 
dual inhibitor, BEZ235 and TSA significantly enhances autophagic cell death and induces 
anti-tumor activities in esophageal squamous cell carcinoma [297] and breast cancer [298] 
by depressing the PI3K/AKT/mTOR signaling pathway and upregulating the expression 
of LC3-II and Beclin1. 
4.8.2. 6-Shogaol 
6-shogaol, an active constituent of dietary ginger, exerts anti-inflammatory and anti-
cancer properties. Treatment with 6-shogaol inhibits autophagy flux by increasing p62 
and LC3 II levels in liver cancer cells. However, 6-shogaol, in combination with TRAIL, 
induces apoptosis via triggering ROS, upregulating p53 expression and altering the mito-
chondrial transmembrane potential (MTP) of these cells [299]. The antitumor activity of 6-
shogaol in HCC indicates that it enhances autophagy by activating ROS and ER stress-
associated proteins, and induces apoptosis by activating caspase-3 in cancer cells [300]. 6-
shogaol inhibits cell survival and stimulates autophagy by suppressing the AKT/mTOR 
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pathway in human non-small cell lung cancer A549 cells [301]. 6-shogaol induces both 
autophagic and apoptotic cell death in colorectal adenocarcinoma HT-29 cells [302]. 6-
shogaol shows anti-tumor effect in cervical carcinoma by triggering the mitochondrial 
pathway of apoptosis and downregulating the PI3K/AKT/mTOR pathway [303]. 6-
shogaol treatment in breast cancer cells results in the suppression of proliferation by the 
significant induction of apoptosis and the inhibition of autophagy by the regulation of the 
Notch signaling pathway (Hes1 and CyclinD1 genes). Here, the inhibition of autophagy 
by 6-shogaol leads to the enhancement of breast cancer cell apoptosis [304]. However, 6-
shogaol induces autophagic cell death in breast cancer cells and CSC-like spheroids via γ-
secretase mediated down-regulation of Notch signaling (reduction in the expression lev-
els of cleaved Notch1 and its target proteins Hes1 and Cyclin D1) [305]. In addition, 6-
shogaol potentiates the anticancer efficacy of 5-FU, oxaliplatin, and irinotecan by activat-
ing apoptosis and autophagy in CRC cells in hypoxic/aglycemic (glucose starvation) con-
ditions [306]. 
4.8.3. 7-Trehalose 
Trehalose is a disaccharide that is present in a wide variety of organisms, including 
bacteria, yeasts, fungi, insects, invertebrates and higher plants, where it may serve as a 
source of energy and carbon. Trehalose is a powerful autophagy inducer used for the 
clearance of misfolded proteins in cells and animal models of neurodegenerative diseases. 
Recently, it has been reported that trehalose induces cytoprotective autophagy and mi-
tophagy (via enhancing autophagic flux) in prostatic cancer cells that show resistance to 
chemotherapy [307]. 
5. Concluding Remarks and Future Directions 
Since the defects of autophagy have been linked to many human diseases, modula-
tion of autophagy can prevent or treat various human cancers. It has been reported that 
autophagy plays a dual role in cancer, showing both anti-tumor and tumor promotion 
effects, depending on the carcinogenic stage, tissues involved, and microenvironment. 
Autophagy can prevent cancer through the clearance of oncogenic factors; however, it can 
promote cancer progression and metastasis in well-established tumors. The inhibition of 
autophagy in chemoresistant cancer cells can cause cell death, while triggering excessive 
and uncontrolled formation, and the accumulation of autophagosomes and auyolyso-
somes can stimulate apoptotic or cell death with autophagic features. The identification 
of natural products as modulators has already provided a significant understanding of 
the molecular mechanisms of autophagy. Recent advances in technology, such as high-
throughput, image-based screens and high-powered scanning microscopy, have been de-
veloped by different labs to identify natural modulators, as well as dynamics of autoph-
agy for quantitative analysis of autophagic machinery. As discussed throughout this re-
view, the anticancer effects of the enormous range of natural products are related to their 
autophagy-modulating actions, either the suppression or induction of autophagy. How-
ever, several obstacles with experimental bases and clinical trials have hindered the direct 
execution of autophagy modulators in the clinic. It is likely that many of these obstacles 
can be circumvented upon the development of more selective autophagy modulators, 
more precise biomarkers of the autophagy machinery and more animal models of autoph-
agy deficiency in vivo. 
Practically, the take home action of autophagy in cancers depends on the type of tu-
mor, stage of tumorigenesis, tumor niches, as well as the genetic, epigenetic and metabolic 
contexts. Discovery of the precise role of autophagy in tumor development and progres-
sion is vital for the development of novel anticancer therapies that target cancer eradica-
tion. In cancer therapy, numerous unresolved problems exist. On the one hand, conven-
tional chemotherapy and radiation therapy leads to increased toxicity in normal cells and 
tumor cells, limiting their use for cancer treatment. Thus, the development new and effec-
tive therapeutic agents with minimal toxicity to normal cells is of paramount urgency. 
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Natural products with anticancer action have expanded their consideration due to their 
favorable safety and efficacy profiles in clinical trials. On the other hand, tumor resistance 
is increasingly incorporated into chemotherapy, radiotherapy or targeted therapy. One of 
the reasons for this augmented resistance is the failure of apoptosis in cancer cells. Au-
tophagy-mediated cell death may be an alternative solution for this problem. Natural 
products that have the capability to manipulate both autophagy and apoptosis may assist 
cancer cell death. In addition, natural products, in combination with conventional thera-
peutic tactics, may offer greater effectiveness against malignancy. Furthermore, natural 
products, such as magnolol [214], which manipulate both autophagy and mitophagy in 
cancer cells (dual mechanism) may be important therapeutic targets [308,309]. In addition, 
natural products that clear lipid droplets via lipophagy-dependent or -independent mech-
anisms may prevent cancer progression, as these organelles are formed in various cancers, 
including breast, prostate, and clear renal cell carcinoma, and play a role in cancer pro-
gression [310,311]. 
A recent article reported the successful application of computer-assisted methods in 
screening a unique and diverse collection of an inhouse library consisting of about 1000 
individual natural products such as alkaloids, terpenoids, Diels–Alder-type adducts, iso-
flavones, chalcones, and cannabinoids. However, the compounds derived from these nat-
ural products have anticancer and antimicrobial properties, which could be controlled by 
autophagic machinery [312]. Interestingly, there is increasing evidence that autophagy 
proteins activate extracellular vesicles’ (EVs) biogenesis. The pathways between autoph-
agy and EVs occur not only in mammalian cells, but also in plants. This can be significant 
in the context of cancer treatment through the interaction between natural products de-
rived from EVs, which are loaded with oncosuppressive cargoes on mammalian cancer 
cells [313]. 
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Abbreviations 
UPS ubiquitin-proteasome system 
ER endoplasmic reticulum 
ATG Autophagy-related genes 
FDA Food and Drug Administration 
IM isolation membrane 
ULK1 Unc-51-like autophagy activating kinase 1 
PI3K Phosphatidylinositide 3-kinase 
mTORC1 mechanistic target of rapamycin complex 1 
AMPK AMP-activated protein kinase 
MOM Mitochondrial outer membrane 
MOMP MOM potential 
ERES ER exit sites 
MAMs mitochondria-associated ER membranes 
PI3P Phosphatidylinositol 3-phosphate 
DFCP1 double FYVE domain–containing protein 1 
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Ubl ubiquitin-like 
LC3 MT-associated protein 1 light chain 3 
LC3-PE LC3-phosphatidylethanolamine 
LIR LC3 interacting regions 
Ambra1 Activating Molecule In Beclin1-Regulated Autophagy Protein 1 
p62/ SQSTM1 Sequestosome-1 
MTs Microtubules 
ALR autophagic lysosome regeneration 
IP3R inositol 1,4,5-trisphosphate (IP3) receptor 
JNK c-Jun N-terminal kinase 
BH3 Bcl-2 homology (BH) domain 3 
3-MA 3-methyladenine 
MLCK myosin light chain kinase 
PLK1 Polo-like kinase 1 
DNA-PK DNA-dependent protein kinase 
ATM ataxia–telangiectasia mutated 
NP Nanoparticle 
NCT National Clinical Trial 
PSM Petrosaspongiolide M 
EPI Epirubicin 
Bcl-2 B-cell lymphoma 2 
TP tea polyphenol 
MTAs MT-targeting agents 
CA-4 Combretastatin A-4 
CA-4P CA-4 phosphate 
NAC N-acetyl cysteine 
ROS reactive oxygen species 
rhArg recombinant human arginase 
5-FU 5-fluorouracil 
VCP Valosin Containing Protein or p97 
XN xanthohumol 
Sal A salvianolic acid A 
Sal B salvianolic acid B 
SCC squamous cell carcinoma 
CCC circulating cancer cells 
PTEN phosphatase and tensin homolog deleted on chromosome 10 
EMT epithelial-mesenchymal transition 
AKT protein kinase B (PKB) 
HIF-1α hypoxia-inducible factor 1α 
VEGF Vascular endothelial growth factor 
HCC hepatocellular carcinoma 
CRC colorectal cancer 
Dox Doxorubicin 
Cdk4 cyclin-dependent kinase 4 
Hsp-90 heat shock protein-90 
PARP-1 poly (ADP-ribose) polymerase 1 
ALL acute lymphoblastic leukaemia 
CQ Chloroquine 
Baf A1 Bafilomycin A1 
OC Oblongifolin C 
GUTK guttiferone K 
v-ATPase vacuolar-type ATPase 
LMP lysosomal membrane permeabilization 
SAR structure-activity relationship 
CR Caloric restriction 
SIRT1 Sirtuin 1 
BNIP3/BNIP3L BCL2/adenovirus E1B 19 kDa protein-interacting protein 3/ligand 
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STAT3 Signal transducer and activator of transcription 3 
RAGE receptor for advanced glycation end products 
MDR1 multidrug resistance protein 1 
P-gp P-glycoprotein 
NLRP3 NLR family pyrin domain containing 3 
EGCG (−)-epigallocatechin-3-gallate 
CGA chlorogenic acid 
EGC (−)-epigallocatechin 
ECG (−)-epicatechin-3-gallate 
NSCLC non-small cell lung cancer 
MAPK mitogen-activated protein kinase 
N-CoR nuclear receptor co-repressor 
HSC70 Heat shock cognate 71 kDa protein 
TFEB transcription factor EB 
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells 
MMP mitochondrial membrane potential 
Nrf2 Nuclear Factor, Erythroid 2 Like 2 
ARDs age-related diseases 
CRM caloric restriction mimetic 
p70S6K phosphorylation of p70 ribosomal protein S6 kinase 
SOCE store operated calcium entry 
TMZ Temozolomide 
MGMT O6-methylguanine-DNA methyltransferase 
TSC2 Tuberous Sclerosis Complex 2 
PKC-δ protein kinase C δ 
TG2 Transglutaminase 
CSCs cancer stem cells 
6-CEPN 6-C-(E-phenylethenyl)naringenin 
BUC bladder urothelial carcinoma 
PERK phosphorylated extracellular signal-regulated kinase 
eIF2α Eukaryotic initiation factor 2α 
CHOP C/EBP homologous protein 
CaMMK Calmodulin- dependent kinase protein kinase 
IRE1α inositol-requiring enzyme 1α 
TNBC triple-negative breast cancer 
MPT mitochondrial permeability transition 
SERCA Sarcoplasmic-/ endoplasmic reticulum sarco/ER Ca2+ ATPase 
TG Thapsigargin 
TBMS1 Tubeimoside-1 
ERK1/2 Extracellular signal-regulated kinase 1/2 
PTP1B protein-tyrosine phosphatase 1B 
DRP1 dynamin-related protein 
EEPP ethanolic extract from P. polyphylla 
DPPE Diosgenin enriched P. polyphylla rhizome extract 
BA Betulinic acid 
GRP78 glucose-regulated protein 78 
CPT Camptothecin 
AP-1 Activator protein 1 
miR-15a microRNA-15a 
BBR Berberine 
PDT photodynamic therapy 
TET Tetrandrine 
APL acute promyelocytic leukemia 
PA pituitary adenoma 
TRAIL Tumor necrosis factor (TNF)-related apoptosis-inducing ligand 
TRAF2 TNF receptor-associated factor 2 
FAK focal adhesion kinase 
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S6K1 70-kDa ribosomal S6 kinase 1 
TQ Thymoquinone 
GBM glioblastoma multiforme 
LXRα liver-X receptors α 
ABCA1 ATP-binding cassette transporter A1 
ccRCC clear cell renal cell carcinoma 
AR androgen receptor 
ω3-PUFAs omega-3 polyunsaturated fatty acids 
EPA eicosapentaenoic acid 
EPADA EPA-dopamine 
DHA docosahexaenoic acid 
DHADA DHA-dopamine 
MM multiple myeloma 
PBMCs peripheral blood mononuclear cells 
DCs dendritic cells 
PPARγ peroxisome proliferator-activated receptor γ 
Delta-T3 vitamin E Delta-tocotrienol 
HDACIs histone deacetylase inhibitors 
TSA trichostatin A 
SAHA suberoylanilide hydroxamic acid 
FOXO1 forkhead box protein1 
PRMT5 protein arginine methyltransferase 5 
TRPV6 transient receptor potential cation channel, subfamily V, member 6 
STC1 stanniocalcin 1 
IGFBP2 insulin-like growth factor (IGF) binding protein-2 
VSOAC volume-sensitive organic anion channel 
TauT taurine transporter 
MTP mitochondrial transmembrane potential 
CLL Chronic Lymphocytic Leukaemia 





NR Not yet recruiting 
U Unknown 
ATRA all-trans retinoic acid 
CyP Cyclophosphamide 
Cape Capecitabine 
PCOS Polycystic ovarian syndrome 
FME familial Mediterranean fever 
HEKs human epidermal keratinocytes 
CSCC cutaneous squamous cell carcinoma cell 
NTM nontuberculous mycobacteria  
LYNUS lysosomal nutrient sensing machinery 
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